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ABSTRACT
Background: Previous studies have found that health insurance and other socio-demographic
factors are important predictors of non-medical use of prescription drugs (NMUPD), their abuse
and dependence, and use of substance abuse treatment. However, the effect of health insurance
in specific subgroups of population on NMUPD, their abuse and dependence, and use of
substance abuse treatment, is largely unknown.
Objective: To determine if the effect of health insurance on NMUPD, their abuse and
dependence, and use of substance abuse treatment differs by socio-demographic factors. The
study also aims to identify prescription drugs that are used non-medically and to assess the
relationship between health insurance and use of such drugs.
Methods: This study used data from 2007 National Survey on Drug Use and Health (NSDUH).
Sample consisted of individuals who were 12 year and older, non-institutionalized. Bivariate and
multiple logistic regression analyses were conducted to estimate the relationship between health
insurance, socio-demographic factors on NMUPD, their abuse and dependence, and use of
substance abuse treatment.
Results: In 2007, self-reported prevalence of NMUPD was eight percent (N=5190). NMUPD
was higher among uninsured individuals. In multivariate analysis, age, race, education, marital
status, type of health insurance, level of income, past year use of tobacco, and alcohol were
significantly associated with NMUPD. Hispanic people with private health insurance, high
school graduates with public health insurance, privately insured individuals with family income
less than $20,000 and $40,000-$74,999 were more likely to use prescription drugs than others.
Drugs most likely to be used non-medically were Vicodin/Lortab/Lorcet (pain relievers), Valium
viii

/diazepam (tranquilizers), methamphetamine, Desoxyn/Methedrine (stimulants), and
Methaqualone/Sopor/ Quaalude (sedatives).
Approximately, one percent of the entire sample and 13% of NMUPD reported abuse
dependence on prescription drugs. The classes of prescription drugs most likely to be abused
were pain relievers, tranquilizers, stimulants and sedatives. Among individuals who used drugs
non-medically, health insurance, age, marital status, general health status and use of tobacco
were significant predictors of abuse/dependence. There were no significant interaction effects
between health insurance and socio-demographic factors on prescription drug abuse and
dependence.
The last part of the study assessed if health insurance improved access to substance abuse
treatment programs among those who reported NMUPD. Approximately 6% of the entire
sample and 73% of the non-medical users and 76% of the prescription drug abusers/dependents
reported some use of substance abuse programs. The Multivariate regression models indicated
that health insurance was not associated with use of substance use treatment program. In
addition, there were no significant interaction effects between health insurance and other sociodemographic and economic factors.
Conclusions: NMUPD, their abuse/dependence, is common in the United States. Most of the
non-medical users of prescription drugs, its abusers/dependents use pain relievers. Health
insurance is associated with NMUPD, its abuse and dependence but not with the use of substance
abuse treatment. Certain subgroups such as high school graduates with public health insurance
privately insured individuals with family income less than $20,000 and $40,000-$74,999 are less
likely to use prescription drugs non-medically. On the other hand, Hispanics with private health
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insurance are more likely to use prescription drugs non-medically than the others. These
individuals are more likely to have lower education as well as poor physical and financial
conditions. It is important that non-medical users, prescription drug abusers/dependents are made
aware of the harms of NMUPD, their abuse and dependence and the benefits of using substance
abuse treatment to overcome these health problems.
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CHAPTER 1
INTRODUCTION
1.1

Specific aims
In the United States, non-medical use of prescription drugs (NMUPD), their abuse and

dependence are major health problems. Estimates based on the 2007 National Survey on Drug
Use and Health (NSDUH) show that approximately 6.9 million individuals (2.8% of the
population) used prescription drugs non-medically in the past month. Pain relievers,
tranquilizers and stimulants were the three most frequently misused therapeutic drug class in
2007 (See Table 1) [1].
Table 1: NMUPD, their abuse and dependence among the U.S. individuals in 2007
Total sample

Pain relievers

Tranquilizers

Stimulants

Sedatives

(in millions)

(in millions)

(in millions)

(in millions)

(in millions)

NMUPD

6.9

5.2

1.8

1.1

0.35

Rx drug
abuse/dependence

2.2

1.7

0.44

0.41

0.2

Studies indicate that non-medical use, abuse and dependence on prescription drugs affect
quality of life and increase morbidity and mortality [2]. Indeed, unintentional drug poisoning
deaths have risen over time, and the misuse of prescription opioids is the primary reason behind
this upward trend [3]. Mortality involving prescription opioid analgesics has increased from
2,900 persons in 1999 to 7,500 persons in 2004 - an increase of 159% in just five years. In 2005,
deaths resulting from the misuse of prescription opioids, benzodiazepines and antidepressants
(45%), exceeded the number of deaths from the illicit use of cocaine, heroin and
methamphetamines/amphetamines (39%) [3].
1

According to a 2002 report, total cost of drug abuse (which also includes illicit drugs)
was $180.8 billion per year. Categories of drug abuse costs were [4]:
Lost productivity - $128.6 billion per year (20%)
Health care costs - $15.8 billion per year (71%)
Criminal justice and social welfare - $36.4 billion per year (9%)
Prior studies indicate that demographic factors such as gender, age, ethnicity, health
status, education, employment and income are significant predictors of NMUPD, their abuse and
dependence [5-13]. Results from these studies point out that individuals who are male, younger,
Whites, unemployed, have fair/poor health status, low education level, and lower income are
more likely to be involved in non-medical use and abuse/dependence of prescription drugs when
compared to other individuals.
Health insurance is an important predictor of NMUPD, their abuse and dependence [5].
Becker et al. (2007) found that uninsured people had 1.2 times greater odds of non-medical use
of sedatives and tranquilizers than insured people. In this study, non-medical use of sedatives and
tranquilizers was 2.3% and approximately 10% of the non-medical users of sedatives and
tranquilizers also met the DSM-IV criteria for abuse or dependence [5]. Despite health insurance
being an important predictor of NMUPD, their abuse/dependence (i.e., prescription drug
disorders) few studies have investigated this relationship in greater length. Literature does not
explain if health insurance has a disproportionate affect among specific subgroups of population
e.g., low-income individuals, unemployed individuals, individuals with poor/fair health status,
etc. Identifying such subgroups would help decision-makers to create more efficient health
insurance policies.
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Prescription drug non-medical users who abuse prescription drugs or become
psychologically dependent on them seek substance use treatment services [4, 14, 15]. The cost
of these treatment services can reach anywhere between $3,840 per admission to $7,415 per
admission [16]. Such high cost of treatment can create financial burden, especially among the
low-income population, leading to non-compliance. Some studies have indicated that health
insurance is an important tool that facilitates access to substance use treatment services among
users of illicit drugs [17] but we do not know if the same holds true for prescription drug
abuse/dependence. The present study aims to address these issues. Results from this study can
help policy-makers in determining whether providing health coverage to the uninsured will help
to control the rising problem of NMUPD and subsequent prescription drug abuse/dependence.
Purpose: The purpose of the study was to determine the association between health insurance
and socio-demographic factors on NMUPD, their abuse and dependence by using data from the
2007 National Survey on Drug Use and Health (NSDUH).
1.1.1 Aims and hypothesis:
Specific aim 1: To estimate the relationship between health insurance and NMUPD,
abuse and dependence, and to assess how socio-demographic and economic factors (age, gender,
race/ethnicity, education, marital status, employment, family/individual income and health
status) modify the association between health insurance and NMUPD, their abuse and
dependence.
Hypothesis (H1): NMUPD, their abuse and dependence will be lower among individuals
with health insurance when compared to the individuals without health insurance. Among the
uninsured, individuals who are young (aged 18-24 years), male, Whites, unemployed, unmarried,
3

belong to the lowest income level, have less than high school education, poor/fair health status,
used tobacco and used alcohol will be more likely to indulge in NMUPD, their abuse and
dependence, than the others.

Specific aim 2: To estimate the relationship between health insurance and probability of
seeking treatment for NMUPD, their abuse and dependence and to assess how age, gender,
race/ethnicity, education, marital status, employment, family/individual income and health status
will modify the relationship between health insurance and probability of seeking treatment for
NMUPD, their abuse and dependence.
Hypothesis (H1): Uninsured individuals will be less likely to seek treatment for NMUPD, their
abuse and dependence than those who have health insurance. Among the uninsured non-medical
users, prescription drugs abusers and dependents, individuals who are young (aged 18-24 years),
male, Whites, unemployed, unmarried, belong to the lowest income level, have less than high
school education, poor/fair health status, used tobacco and used alcohol will be less likely to seek
treatment for drug abuse and dependence than others.

Specific aim 3: To quantify and estimate bivariate associations between therapeutic
classes of prescription drugs used non-medically and health insurance.
Hypothesis (H1): Non-medical use of different therapeutic classes of prescription drugs
will vary by type of health coverage.

4

1.2

Study background

1.2.1 Defining non-medical use of prescription drugs, abuse and dependence:
Prescription drug can be defined as a product that requires a doctor‘s authorization or a
prescription to purchase [18, 19]. The Diagnostic and Statistical Manual of Mental Disorders-4th
edition (DSM-IV) defines substance abuse and dependence, however, there is no consensus
regarding a definition of NMUPD in the literature [20, 21]. Devenyi (1985) defined drug abuse
as improper use of a drug in terms of its therapeutic indication or dose, whereas drug dependence
is a physical and psychological dependence on drugs [22].
Hertz and Knight (2006) suggested that abuse is ―use of a controlled substance outside
normally accepted standards of use, resulting in disability or dysfunction,‖ whereas misuse is
use of a controlled substance for reasons other than that for which it was prescribed or in dosage
form different from one that was prescribed that does not lead to disability among the misusers
[23]. Culberson and colleagues (2008) developed a continuum to distinguish misuse of
prescription drugs by the patient as well as by the practitioner, and abuse and dependence on
prescription drugs by the patient. According to the continuum, misuse of prescription drugs by
the patient involves use of prescription drugs in inappropriate doses, for unintended purposes,
with other medications or alcohol, and skipping doses or storing drugs. A practitioner misuses
the prescription when he/she prescribes a medicine for an inappropriate indication, in an
inappropriate dose, and fails to ensure the proper use of the medication. Prescription drugs abuse
leads to adverse social, personal and physical outcomes, whereas prescription drug dependence
leads to tolerance to the effect of drugs and withdrawal symptoms when the use of the
prescription drug is reduced or stopped [24].

5

In summary, each author has defined misuse, dependence and abuse of prescription
drugs as per the objectives/motives of their study as well as clinical or psycho-social beliefs
regarding what constitutes appropriate use of prescription medications. Clearly, the terms
prescription drug abuse and dependence have been used idiosyncratically and interchangeably
[22, 25]. If one measures NMUPD, their abuse and dependence by using the method proposed by
Culberson et al. (2008) then one would over-estimate NMUPD, their abuse and dependence
since this method is not restricted to misuse of prescription drugs by the patients but also
includes misuse of prescription drugs by the physicians. Additionally, the method considers
skipping doses/storing drugs as misuse. Thus, the definition of misuse of prescription drugs
provided by Culberson and colleagues is very broad and would lead to an over-estimation of the
NMUPD and their abuse/dependence. On the other hand, use of definition suggested by Devenyi
(1985) would provide narrow estimates of non-medical use, abuse and dependence on the
prescription drugs as this definition is limited to dose and therapeutic indication of the
prescription drugs used but does not incorporate cases where dosage form or route of
administration of the prescription medication is modified. However, all definitions agree that
prescription drug misuse is use of prescription drugs without a doctor‘s order or improper use of
a prescription drugs either in different strength, dose, route or indication than recommended by
the physician. Additionally, misuse of prescription drug is a broader term that includes NMUPD,
abuse of and dependence on prescription drugs. If repeated misuse of prescription drug/s leads
to effects that are detrimental to either an individual's physical and mental health or to the
welfare of others and if an individual continues with this risky behavior despite harmful personal
and social consequences, then the condition is known as prescription drug abuse. Furthermore,
persistent long-term abuse can lead to tolerance to the effects of the prescription drug/s and if
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person suffers from the withdrawal symptoms when the use of drug is reduced or stopped, then
the condition is known as prescription drug dependence.
This study uses definitions from NSDUH to define NMUPD, their abuse and dependence.
NSDUH survey items have been evaluated for their accuracy and reproducibility of results [26].
A study conducted to determine the reliability of the responses provided by the respondents
found that the survey provided consistent measures of substance use and mental health [27].
NSDUH categorizes a person as a non-medical user of prescription drugs if s/he ―had used at
least one medication (either pain relievers, tranquilizers, stimulants, or sedatives) without a
prescription or had used a medication simply for the experience or feeling that it caused‖ [28].
NSDUH defines prescription drug abuse and dependence based on the DSM-IV criteria
of substance abuse and dependence [20]. The data code an individual as dependent on
prescription drugs if s/he meets three or more of the seven dependence criteria. The first six
criteria are: 1) respondent has to spend a great amount of time to get, use or to recover from the
effects of the prescription drug; 2) uses the prescription drug more often than required and is
unable to follow the set limits of use; 3) requires more amount of prescription drug than before to
get the desired effects or notes that the same amount of prescription drug has lesser effect than in
the past; 4) is unable to cut down or stop using the prescription drugs every time the respondent
tries to do so; 5) continues to use the prescription drugs despite emotional, mental and physical
problems; 6) prescription drug use leads to stoppage or decrease in involvement or participation
in important activities. The seventh criterion is whether the respondent has experienced certain
withdrawal symptoms based on the type/s of prescription drug/s used.
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The data code an individual as a prescription drug abuser if s/he meets one or more of the
four DSM-IV abuse criteria and also has been determined not to be dependent on the respective
prescription drug/s in the past year. The abuse criteria are: 1) respondent has serious problems at
home, work or school due to the use of prescription drugs; 2) uses the prescription drug regularly
and then also engages in activities that might put him/her in physical danger; 3) use of the
prescription drug leads to legal problems 4) suffers personal problems that occur probably due to
the use of prescription drug/s but the respondent continues using the prescription drugs despite
these problems.
Using these criteria, a series of questions were formulated in NSDUH to determine
whether a person was suffering from prescription drug dependence or abuse [29]. These
questions were re-coded to generate variables that helped determine whether a person engaged in
prescription drug abuse or dependence during his lifetime/past year/past month. These datagenerated recoded variables were then used to determine whether a person was suffering from
prescription drug dependence or abuse.
1.2.2 Prescription drugs with potential for non-medical use abuse and dependence:
Prescription drugs are classified into five schedules based on medical use of a drug, its
abuse potential, safety, and dependence liability. These are schedule I, II, III, IV, and V.
Schedule I drugs have the highest potential for abuse and do not have any accepted medical uses.
Schedule II drugs have high abuse potential and approved medical uses but with strict
restrictions. Their use can cause severe psychological or physical dependence and as such these
drugs are available only by un-refillable prescription. Schedule III drugs have lower abuse
potential as compared to the schedule I and II drugs, but their use can still cause psychological or

8

physical dependence. Schedule IV drugs have relatively lower abuse potential than the Schedule
III drugs. Both schedule III and IV drugs are available by prescription, and a patient can have
only five refills in six months. Schedule V contains drugs that have low potential for abuse
relative to the drugs or other substances in Schedule IV [23, 30, 31]. These schedules are
summarized in Table 2.
Table 2: Drug Enforcement Administration drug schedules
Drug schedule

Abuse/dependence
potential

Accepted
medical use

Need for a
prescription

Examples

Schedule I

High

No

Not
applicable

Flunitrazepam, LSD, PCP

Schedule II

High

Yes

Yes (unrefillable)

Methadone, cocaine, oxycodone
(Percodan®), methylphenidate
(Ritalin®) and dextroamphetamine
(Dexedrine®)

Schedule III

Low/moderate

Yes

Yes (five
refills only)

Anabolic steroids, some barbiturates

Schedule IV

Low

Yes

Yes (five
refills only)

Darvon, Talwin, Equanil, Valium and
Xanax

Schedule V

May or may not

Yes

No

Over-the-counter medications

The following classes of prescription drugs have the greatest potential for non-medical
use, abuse and dependence a) pain relievers (narcotic analgesics); b) tranquilizers
(benzodiazepines); c) stimulants; d) and sedatives (barbiturates). Pain relievers include fentanyl,
morphine and its derivatives, such as codeine, opium and its derivatives such as oxycodone,
meperidine, hydromorphone, hydrocodone and propoxyphene. Tranquilizers are used to reduce
stress and tension as they have soothing or calming effect on mood, thought and behavior [32].
These include anti-anxiety agents such as alprazolam, citalopram, clorazepam, diazepam,
lorazepam, and flunitrazepam. Stimulants are drugs that increase alertness and awareness,
9

improve appetite, mood and feeling of well-being [33]. Examples of stimulants are various
amphetamines such as laevoamphetamine, dextroamphetamine, methamphetamine and
methylphenidate. Sedatives reduce excitement and anxiety and are used to induce drowsiness or
sleep. These include barbiturates such as amobarbital, pentobarbital, phenobarbital, secobarbital
and tuinal. Table 3 below lists these drugs with their drug class, generic name, brand name, street
name, abuse potential based on the Drug Enforcement Administration (DEA) schedule and their
therapeutic use [30, 31, 34, 35].
Some of the over-the-counter (OTC) drugs such as cough suppressants, motion sickness
pills, and sleep aids contain dextromethorphan, dimenhydrinate and acetamionphen that are not
controlled under the Controlled Substances Act (CSA) of 1970. Therefore, these drugs do not
require a prescription but still have high potential for non-medical use, abuse and dependence.
Although non-medical use, abuse and dependence on OTC drugs are important issues, this study
is restricted to prescription drugs only.
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TABLE 3: Prescription drugs with generic names, brand names, street names, DEA schedules and therapeutic uses
DRUG CLASS

GENERIC NAME

BRAND NAME

STREET NAME

ABUSE
POTENTIAL
/ DEA
SCHEDULE

THERAPEUTIC USES

Codeine

Codeine Sulfate, Codeine Phosphate

Empirin with Codeine, Fiorinal
with Codeine, Robitussin A-C,
Tylenol with Codeine, Captain
Cody, Cody, schoolboy, (with
glutethimide) doors and fours,
loads, pancakes and syrup

V

Mild–moderate pain and
symptomatic relief of cough

Fentanyl

Ionsys, Duragesic-50, Duragesic-25,
Actiq, Duragesic, Fentora, Duragesic100, Duragesic-75, Fentanyl Citrate,
Sublimaze, Duragesic-12

Actiq, Duragesic, Sublimaze;
Apache, China girl, China
white, dance fever, friend,
goodfella, jackpot, murder 8,
TNT, Tango and Cash

II

Short-acting analgesic in
anesthesia

Morphine

OMS, Morphine IR, Doloral Sirop,
Morphitec, Oramorph SR, Mos-60,
MS/S, Duramorph PF, Astramorph PF,
PMS-Morphine, Rescudose, Morphine
HP, M O S, Morphine Sulfate,
Morphine Extra Forte, Mos-40, Statex,
MSIR, Alti-Morphine, M-Eslon,
Morphine Forte, Ratio-Morphine SR,
Mos, Morphine Sulfate SR, Kadian,
Roxanol, RMS, Mos-50, Avinza,
Morphine LP Epidural, Infumorph, MS
Contin, Doloral, M. O. S., Roxanol-T

Roxanol, Duramorph, M, Miss
Emma, monkey, white stuff

Severe chronic pain, adjunct to
general anesthesia, in epidural
anesthesia or intrathecal
analgesia, for palliative care,
antitussive, treatment of
dyspnea, antidiarrheal

Oxycodone

OxyContin, Percolone, Roxicodone
Intensol, Oxyfast, Endocodone, ETHOxydose, Roxicodone, Dazidox,
OxyIR, Oxycodone Hydrochloride ER,
Oxycodone Hydrochloride

Oxy, O.C., Hillbilly heroin,
Oxycotton and Killer, Oxy80

Pain

Meperidine

Demerol HCl, Meperidine
Hydrochloride, Mepergan, Pethadol,

PAIN RELIEVERS

Pain, adjunct to anesthesia and
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DRUG CLASS

GENERIC NAME

BRAND NAME

STREET NAME

ABUSE
POTENTIAL
/ DEA
SCHEDULE

Pethidine HCL

THERAPEUTIC USES

preoperative sedation

Hydromorphone

Palladone, Dilaudid, Hydromorphone
Hydrochloride, Hydrostat IR,
Dilaudid-HP, Dilaudid-5, Hydal,
Sophidone, Hydromorfan,
Hydromorphan, Laudicon

Dust, Juice, Smack, D,
Footballs

Pain, as an antitussive

Hydrocodone

Hydrocodone Bitartrate

Vicodin, Lortab, Lorcet,
Hycodan, Vicoprofen, vikes
and hydros.

Pain, as an antitussive

Combination with others: Anexsia,
Hycodan, Hycomine, Lorcet, Lortab,
Tussionex, Tylox and Vicodin
Propoxyphene

Propoxyphene Hydrochloride, PP-Cap,
Darvon-N, Darvon

IV

Management of mild to
moderate pain

IV

Anxiety disorders, agoraphobia

TRANQUILIZERS (anti-anxiety agents)
Benzodiazepines

Alprazolam

Xanax XR, Xanax, Niravam,
Alprazolam ER

Parachuting, Z-bars, bars,
Xanies

Clonazepam

Klonopin, Clonopin

Pins, Super Valium

Relief of symptoms of anxiety,
for petit mal seizures, akinetic
seizures and myoclonus, as well
as Lennox-Gastaut syndrome

Diazepam

Dizac, Zetran, Valrelease, Diastat
AcuDial, Diastat, Valium, Diastat
Pediatric

Vals, blues, mother's little
helper, drunk pills, V, ludes,
candy (pills), benzos, downers.

Anxiety disorders, status
epilepticus, skeletal muscle
relaxation, anesthetic
premedication

Lorazepam

Lorazepam Novaplus, Ativan

None

Anxiety disorders, preanesthetic medication

Flunitrazepam

Rohypnol

Rophy, ruffels, roachies,
roofies, ruffies, ruff up, rib,
roach 2 (R2), roche, rope,
ropies, circles, circes, forget it,
forget-me-pill, Mexican
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I

Not approved by FDA

DRUG CLASS

GENERIC NAME

BRAND NAME

STREET NAME

ABUSE
POTENTIAL
/ DEA
SCHEDULE

THERAPEUTIC USES

II

Narcolepsy, attention deficit
disorder with hyperactivity

Valium, and Run-Trip-AndFall, roofinol
STIMULANTS
Amphetamines

Amphetaminedextroamphetamine

Adderall XR, Adderall

Beans, Christmas trees, Pep
pills, Bennies, Dexies, Speed,
Black Beauties, Double
Trouble, Uppers
None

Laevoamphetamine racemic mixture of
amphetamine (dlamphetamine)

Benzedrine, Obetrol

Dextroamphetamine

Dextrostat, Dextroamphetamine
Sulfate, Dexedrine, Dexedrine
Spansule

Methamphetamine

Methedrine

Methylphenidate

Metadate, Ritalin-SR, Daytrana,
Methylphenidate Hydrochloride,
Methylin ER, Methylin, Ritalin LA,
Methylphenidate Hydrochloride SR,
Metadate ER, Ritalin, Concerta,
Metadate CD

Amobarbital

Amytal

Downers, blue heavens, blue
velvet, blue devils

III

Insomnia, preoperative sedation,
emergency management of
seizures

Pentobarbital

Nembutal

Nembies, yellow jackets,
abbots, Mexican yellows

II

Insomnia, preoperative sedation,
emergency management of
seizures

Anorectant

bennies, black beauties,
crosses, hearts, LA turnaround,
speed, truck drivers, and
uppers
Xtc, MDMA, Adam, X,
Ecstasy, Crank, Meth, Jib, Ice,
Crystal, Tina, Glass, Bathtub
crank, speed, chalk, go fast
Kibbles and Bits, KiddyCocaine, Pineapple, R-Ball,
Skippy, Smart Drug, Smarties,
Vitamin R, West Coast, JIF,
MPH

Narcolepsy, attention deficit
disorder with hyperactivity

Narcolepsy, attention deficit
disorder with hyperactivity

Attention deficit disorder with
hyperactivity

SEDATIVES
Barbiturates
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DRUG CLASS

GENERIC NAME

BRAND NAME

STREET NAME

ABUSE
POTENTIAL
/ DEA
SCHEDULE

THERAPEUTIC USES

Phenobarbital

Phenobarbital

Karachi, purple hearts, goof
balls

IV

Seizure disorders, status
epilepticus, daytime sedation

Secobarbital

Seconal

Reds, red birds, red devils,
lilly, F-40s, pinks, pink ladies,
seggy

II

Insomnia, preoperative sedation

Tuinal

Combination of two barbiturate salts
(secobarbital sodium and amobarbital
sodium) in equal proportions

Rainbows, reds and blues,
tooies, double trouble, gorilla
pills, F-66s

II

Sedation
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1.2.3 Prevalence of non-medical use of prescription drugs, abuse and dependence:
An earliest estimate of non-medical use of prescription drugs comes from the study
conducted by Simoni-Wastila et al. (2004). The authors used data from 1991-93 National
Household Survey on Drug Abuse, which is now known as the National Survey on Drug Use and
Health (NSDUH). NHSDA is an annual survey that collects information about the prevalence of
substance misuse among the non-institutionalized population aged 12 years or older [12, 36].
According to the analysis, there were 8.2 million past year non-medical users of prescription
drugs (4% of the U.S. population). Of which 1.3 million (0.62%) engaged in heavy NMUPD or
experienced drug dependence [9, 12].
Information about change in the prevalence of NMUPD is also present in the study
conducted by Blanco et al. (2007). They used National Longitudinal Alcohol Epidemiologic
Survey (NLAES) conducted in 1991-92 and its descendant, National Epidemiologic Survey on
Alcohol and Related Conditions (NESARC) conducted in 2001-02 to determine changes in the
prevalence of NMUPD during this decade. NESARC is a longitudinal survey that primarily
collects information about use of alcohol in the civilian, non-institutionalized population aged 18
year and older. Additionally, it provides information on prevalence of non-medical use of
prescription opioids, sedatives, tranquilizers and stimulants. Their analysis showed that NMUPD
increased significantly from 1.5% in 1991-92 to 2.3% in 2001-02 (53% increases). The largest
increase was observed for sedatives (350%); followed by prescription opioids (117%) and
tranquilizers (20%). All these changes were significant at one percent alpha level except for the
change in the non-medical use of tranquilizers. No change was found in the non-medical use of
prescription stimulants during these years. The study also showed that the prevalence of DSM-IV
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drug use disorders increased by from 0.3% in 1991-92 to 2.3% in 2001-02 (p<0.001), which
represents an increase of 67% during this decade [36].
Estimates from the 2000-04 NSDUH show that 14.8 million persons aged 12 years and
older (6.2%) used prescription drugs non-medically in the past 12 months. Among these nonmedical users, 11.3 million persons (4.8%) used pain relievers; 5.0 million (2.1%) used
tranquilizers; 3.0 million (1.2%) used stimulants, and 850,000 (0.4%) used sedatives.
Additionally, there were 6.1 million (2.5%) non-medical users in 2004, of which 2.0 million
were also involved in their abuse and dependence [37].
Recent data from 2007 NSDUH show that about 6.9 million (2.8%) U.S. individuals aged
12 years and older used prescription drugs non-medically in the past month. Of these, 5.2 million
(2.1%) used pain relievers, 1.8 million (0.72%) used tranquilizers, 1.1 million (0.44%) used
stimulants, and 346,000 (0.14%) used sedatives non-medically. A similar trend regarding
NMUPD has been reported each year since 2002 [1]. The number and percentage rates of
NMUPD for the 2007 year were similar to the 2006 year. However, number and percentage of
nonmedical users of stimulant decreased from 0.6% in 2006 to 0.4% in 2007. Socio-demographic
characteristics of these individuals suggest that the young adults aged 18-20 years had the
highest rate (21.6%) of current (past month) NMUPD whereas individuals aged 65 or older
(0.7%) had the lowest rate of NMUPD. Males and females had similar rates of past-month nonmedical use of tranquilizers, stimulants, sedatives and OxyContin®. Among different races,
Asians had the lowest prevalence of NMUPD (4.2%) whereas American Indians and Alaska
Natives had the highest rate of NMUPD (12.6%). However, there were no statistical significant
differences in the rate of NMUPD among different races in 2006 and 2007. There was a negative
relationship between education and NMUPD. College graduates had the lowest rate of NMUPD
16

(5.1%) vs. the high school graduates (9.3%). As expected from previous years‘ data, rate of
NMUPD was highest for unemployed individuals (18.3%) than for those who were employed
part time (10.1%) or full time (8.4%). Referring to different geographic locations, prescription
drugs non-medical use in 2007 was highest in the West (9.3%), followed by Midwest (7.9%),
Northeast (7.8%), and it was lowest in the South (7.4%). Among people using prescription drugs
non-medically, 2.2 million were involved in their abuse and dependence. Most of these
individuals abused/were dependent on pain relievers (1.7 million), followed by tranquilizers
(0.44 million), stimulants (0.41 million) and sedatives (0.2 million) [1].
Monitoring the Future (MTF) survey looks at the long-term annual prevalence and
perceptions of the drug use specifically among high school students i.e., those students who are
in the 8th, 10th, and 12th grades and in a subsample of formerly surveyed high school graduates
[38-41]. According to the survey, in 2005, NMUPD was highest in the age group 18 to 20 years
(22.2 %), which was similar to that reported in the 2007 NSDUH. In contrast to the types of
prescription drugs used non-medically nationally, high school students generally used stimulants
non-medically (10%), followed by opioids (9.2%), and sedatives and tranquilizers (6.2% each).
Among 12th graders, increases in annual non-medical use of prescription drugs during 1991-2007
was highest for opiates (3.5% to 9.2%), followed by sedatives and tranquilizers (2.8% to 6.2%)
and lowest for stimulants (7.1% to 10%) [40, 41]. This indicates that more 12th graders are using
prescription drugs non-medically in recent times when compared to the previous years. This
matter is of serious concern, especially the non-medical use of opioids, which has shown the
highest increase in the rate of NMUPD. This might be due to the decrease in the perceived risk
of prescription drugs among these students as has been observed for the use of other illicit drugs
[41]. Moreover, students perceiving prescription drugs as less harmful have been found to be at
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higher risk of their nonmedical use than the others [42, 43]. Other reasons for increase in the
abuse of prescription drugs include aggressive marketing by pharmaceutical companies, growing
acceptance of these drugs in society and the perception that these drugs are safe to use [44]. This
highlights the need for targeted prevention and educational interventions that make the students
aware of the harms caused by non-medical use, abuse and dependence on prescription drugs.
Prevalence of NMUPD, their abuse and dependence reported in different studies are summarized
in Table 4.
Table 4: Prevalence of NMUPD, their abuse and dependence: results from different studies
Rx drugs
abuse

Source

Dataset

NMUPD

Simoni-Wastila et al., 2004

1991-93 NHSDA

4%

Blanco et al., 2007

1991-92 NLAES
and 2001-02
NESARC

1.5% in 1991-92
2.3% in 2001-02

0.3% in 1991-92
2.3% in 2001-02

DHHS, 2008a

2004 NSDUH

2.5%

0.83%

DHHS, 2008b

2007 NSDUH

2.8%

0.89%

-

Rx drugs dependence
0.62%

1.2.4 Summary
Prevalence of life-time non-medical use/abuse of prescription drugs is approximately
20% (48 million persons aged 12 years and older) and this has increased by four percentage
points during 2004-07. Increase of non-medical use/abuse of prescription drugs is higher among
young adults aged 18-25 years (6.4%) when compared to adolescents aged 12-17 years (3.3%)
[45]. Among 12th graders, the increase in rate of non-medical use is highest for pain medications
followed by sedatives, tranquilizers and stimulants. Individuals who are male, White, 18-24
years old, have poor/fair health status, use alcohol and/or illicit drugs have been found to be at
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higher risk for NMUPD, abuse and dependence. Individuals living in the West, those who are
unemployed and have less than college education are more likely to use prescription drugs nonmedically than their counterparts.

1.3

Significance of this study
Men and women who use prescription drugs non-medically are also more likely to smoke

cigarettes, drink alcohol (or binge drink), use illicit/prescription drugs [7, 46, 47]. Concomitant
use of prescription drugs and other substances can lead to harmful drug-drug interactions and
other life threatening consequences apart from their direct effects. Non-medical users of
prescription drugs are also at greater risk of developing prescription drug abuse, dependence and
other behavioral problems. Indeed, prescription drug abuse and dependence among the nonmedical users of prescription drugs is increasing. Blanco and colleagues (2007) found that
prescription drug abuse or dependence changed from 0.3% (in 1991-92) to 0.5% (in 2001-02),
which suggests a significant increase of 67% (p < 0.001) during this decade [36].
Non-medical use of prescription drugs through I.V. route makes the non-medical user
susceptible to other co-morbidities as injection drug use has been found to be the primary risk
factor for the spread of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [48].
Havens and colleagues (2007) found that the prevalence of hepatitis C was higher among the
injection users of opioid analgesics (14.8%) than people using opioids analgesics orally (1.7%)
[49]. Drug abuse has been found to be a significant risk factor for the prevalence of
HIV/Acquired Immune Deficiency Syndrome (AIDS). A report from NIDA suggests that there
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were approximately 1 million people suffering from HIV/AIDS in 2003, and 33% of these cases
were directly or indirectly related to use of drugs through I.V. route [50].
Increase in morbidity due to NMUPD, abuse and dependence has also led to a rise in
emergency department (ED) visits owing to their specialty treatment. Some 741,425 ED visits in
the United States in 2006 were associated with the non-medical use of prescription drugs, OTC
drugs and dietary supplements. Most of these visits involved non-medical use of more than one
type of drugs (54%). Number of individuals entering ED for abuse of drugs was even higher i.e.,
1.7 million and 28% of these visits were related to the abuse of drugs [45, 51, 52].
NMUPD, their abuse and dependence have also led to increase in mortality. Accidental
deaths due to NMUPD have increased over time. Prescription opioids are the primary reason
behind this upward trend, and mortality involving pain killers has increased from 2,900 in 1999
to 7,500 in 2004. This represents an increase of 160% in five years [3].
Rise in ED visits, morbidity and mortality associated with the non-medical use, abuse and
dependence on prescription drugs has imposed an economic burden on patients as well as on
society [4, 53, 54]. The total economic cost associated with drug abuse has increased from
$107.6 billion in 1992 to $180.9 billion in 2002. The largest proportion of the costs of drug abuse
was associated with lost productivity (71.2%), followed by non-health ―other‖ costs (20.1%) and
health-related costs (8.7%). The loss of productivity represents loss of potential resources such
as the inability to contribute in the labor market and in household activities due to the impact of
drug abuse. The estimated productivity losses in 1992 were about $69.4 billion, which rose to
$128.6 billion in 2002. The ‗other cost‘ involves costs associated with the criminal justice
system, crime victim costs, and expenses incurred for the administration of the social welfare
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system, and it was $36.4 billion in 2002. The ‗health care cost‘ was approximately $16 billion in
2002. The prime reason behind this cost was the monies spend on community-based specialty
treatment for drug abuse [4, 54]. Among the four classes of therapeutic medications, prescription
opioids have the highest rate of non-medical use and abuse [55]. Analysis of costs associated
with abuse of prescription opioid analgesics reveals that the total costs of opioid analgesic abuse
was $8.6 billion in 2001 (or $9.5 billion in 2005 dollars). Of this amount, $2.6 billion were
healthcare cost, $1.4 billion were criminal justice cost, and $4.6 billion were workplace costs
[56]. This clearly shows that the non-medical use, abuse of/dependence on prescription drugs
has a negative financial impact on the people misusing prescription drugs as well as on society. It
causes unnecessary utilization of health care resources, leading to an increase in the health care
and other costs.
Health insurance is an important predictor of NMUPD, their abuse and dependence [5],
however, this relationship between health insurance and these behavioral problems has not been
studied in detail. Becker and colleagues (2007) found that uninsured people were 1.2 times more
likely to use prescription drugs non-medically than insured people. Uninsured individuals have
also been found to be more likely to suffer from opioid use disorder than insured individuals [6].
This study will help determine whether there is an association between health insurance and nonmedical use, abuse and dependence of other prescription drugs and how this relationship differs
in specific subgroups of population. It is important to study this relationship because health
insurance is one of the measures that can be subjected to policy change [57]. If uninsured
individuals are more likely to indulge in prescription drug use problems than insured people,
then providing health insurance to the uninsured will be an efficient way to control this problem.
The results of this analysis will also help to identify specific groups of individuals (with or
21

without health coverage) who are more likely to engage in NMUPD, their abuse and dependence.
This in turn can help health care providers as well as prevention and treatment program
developers to become knowledgeable of risk factors and the operating interaction between them.
Most of the individuals who use prescription drugs non-medically and abuse or depend
on them do not seek substance abuse treatment [58] because they feel treatment costs too much
and that they cannot afford it [59]. Past literature has found mixed association between health
insurance and probability of seeking treatment among drug abusers/dependents. Some studies
have observed that health insurance does not affect the receipt of treatment [6, 60, 61] whereas
other studies have found that the uninsured are less likely to use treatment services than the
insured [6, 62-64]. One study noted that health insurance plays a significant role in completion of
the substance use treatment among the substance abusers [65]. Clearly, the relationship between
health insurance and use of substance abuse treatment for NMUPD, their abuse and dependence
is unknown. This study will add knowledge to this under-researched area. Health insurance does
not play an independent role in use of treatment, but different socio-demographic factors also
affect the use of treatment services (Weisner, et al., 2002). Thus, it‘s important to see how the
association between health insurance and utilization of substance abuse services is modified by
socio-demographic characteristics, which also was examined in this study. This will help policymakers determine whether providing health coverage to the uninsured will help provide
treatment to those who are in need of it but could not use it due to cost as a barrier.
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CHAPTER 2: LITERATURE REVIEW
This chapter presents a review of the literature. It begins with a review of literature regarding
health insurance and its relation with the NMUPD, drug abuse and dependence, and use of
substance use services. The latter section describes various predictors and their association with
NMUPD, drug abuse and dependence, and use of substance use services.

2.1

Impact of health insurance on NMUPD, their abuse and dependence
Association between substance use problems (use of illegal drugs e.g., heroin, cocaine)

and health insurance has been well established [60, 62, 64, 66-70]. In these studies, uninsured
individuals have been found to have higher odds of substance use (OR=1.70; CI=1.39-2.07),
abuse and dependence (OR=1.44; CI=1.04-2.00) than those who are insured. Literature that has
examined the relationship between health insurance and prescription drug use is sparse. Kroutil
et al. (2006) observed that uninsured individuals were more likely to use prescription drugs nonmedically when compared to insured individuals and the risk of NMUPD was (36%) lowest
among individuals with Medicaid coverage [71]. Becker and colleagues (2007) found that the
uninsured individual had greater odds (OR=1.2; CI=1.0-1.4) of using sedatives and tranquilizers
non-medically than insured adults [5]. In their other study, they found that people with Medicaid
coverage (OR=1.70; CI=1.03-2.70) had higher odds of opioids abuse and dependence than
people without Medicaid coverage [6]. This could be so because individuals without helath
coverage or those who have Medicaid coverage are more likely to be poor and uneducated.
Hence, they are less likely to perceive the risk associated with NMUPD and their
abuse/dependence which places them at higher risk of prescription drug aubse/dependence.
23

Another possible reason could be that health insurance provides financial access for the use of
prescription drugs [72] and this use in the long run may translate into non-medical use, abuse or
dependence on prescription drugs. However, largely the relationship between health insurance,
non-medical use, prescription drug abuse and dependence still remains unclear [5, 6, 62].

2.2

Impact of health insurance on the use of substance abuse treatment services
Past literature suggests mixed association between health insurance and use of substance

abuse treatment among people who used substances. Wu and Ringwalt (2005) found that
uninsured people were more likely to use substance abuse services than the insured individuals
[67]. In contrast, Schoenbaum and associates (1998) found that of all the members who were
covered under private, employer-sponsored, managed behavioral health care plans, only 0.3% of
the plan members used any substance abuse services [73]. Possible reasons could be that these
individuals do not want to get noticed by their employer or they may be unaware that substance
abuse treatment is covered by their health insurance as a study found that 25%-38% of the
employees who used such services were not aware that their health insurance covered substance
abuse services [74, 75].
Other studies have observed that health insurance aids in making use of substance abuse
services [64, 69] and that insured people are more likely to use them than the uninsured
(OR=6.0; significant at p <0.01). This is perhaps because their health insurance subsidizes or
reimburses the use of substance abuse services. Among insured individuals, use of substance use
services has also been found to differ by type of health insurance coverage. People using
treatment programs for alcohol, drug abuse and mental health problems have been found to get it
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through Medicaid or through other public insurance [64, 69, 70]. Similarly, McAlpine et al.
(2000) found that people with public insurance were six times more likely to have access to
specialty care than uninsured individuals. It is possible that public insurance is acting as an
important source for providing substance use treatment to the people of lower socioeconomic
status (SES) [68, 69]. In contrast to the aforesaid results, some studies did not observe any
association between health insurance statuses or type of health insurance and the receipt of/entry
to drug abuse treatment [6, 60, 61].

2.3

Predictors of NMUPD, their abuse and dependence
Non-medical use of prescription drugs, their abuse and dependence have been found to

differ by demographic and economic factors. These include age, gender, race/ethnicity,
education, marital status, employment, family income, health status, use of tobacco and use of
alcohol. This section deals with the impact of these predictors on NMUPD, their abuse and
dependence.
Age: Young individuals (18-24 years) were found to be at higher risk of using
prescription drugs non-medically than older individuals (65 years and above) [5, 12, 36, 76].
This could be due to the decrease in the perceived risk of prescription drugs among young
individuals as a study found that the students studying in 12th grade perceive illicit drugs as less
harmful [41], and the same might hold true for NMUPD. This observation is further supported
by the fact that students who perceive prescription drugs as less harmful were found to have a
higher risk of using drugs non-medically than the students who perceive prescription drugs as
more harmful [42, 43]. Some studies also reported higher likelihood of NMUPD among older
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individuals [9, 12], but NMUPD among older individuals has been mostly found to be accidental
rather than intentional as opposed to the non-medical use observed among children and adults
[77].
Results from the previous literature suggest mixed association between age and
prescription drug abuse/dependence [36, 78, 79]. In addition, individuals who start NMUPD at
the age of 13 years or before have been found to be at higher risk of developing prescription drug
abuse and dependence than those who engage in NMUPD after 21 years of age [7].
Gender: Studies indicate mixed association between gender and NMUPD. Women have
been found to be at higher risk for NMUPD and prescription drug disorders than men during
1991-92 [9, 12, 36, 47] but this was not the case in 2001-02 [62, 80], and 2004 [81]. Other
studies have also found males to have higher prevalence of NMUPD than females [82-84].
However, in 2007, males and females were reported to have similar rates of past-month use of
tranquilizers, stimulants, sedatives and OxyContin® [55]. Gender has also been found to
influence the type of prescription drug abused or used non-medically. Women have been
observed to be at higher risk of non-medical use of tranquilizers and narcotic analgesics but not
for sedative-hypnotic and stimulant use [12, 36]. This might be due to the greater exposure of
women to prescription drugs as research has shown that women are more likely to be prescribed
prescription drugs with high abuse potential [72, 77, 85-87]. This could be because women have
poorer health or better access to medical care when compared to men [72].
Race/ethnicity: Significant racial and ethnic differences have been observed in the
NMUPD, prescription drug abuse and dependence. In 1991-93, Whites have been found to be
more likely to use prescription drugs non-medically [9, 12, 36]. However, in 2001-02, Native
Americans had the highest likelihood of NMUPD, their abuse and dependence [80]. Recent
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national estimates from 2006 and 2007 NSDUH reveal a similar picture where American Indians
or Alaska Natives (12.6%) had the highest rate of non-medical use and Asians (4.2%) had the
lowest rate of NMUPD [55].
Education: Results from various national surveys suggest that education is inversely
related to NMUPD, their abuse and dependence. As expected, individuals with a college
education have been found to be at lower risk of NMUPD, drug abuse and dependence than
those with a lower education [5, 7, 9, 36, 55, 80, 81, 88]. In contrast, Huang and colleagues
(2006) found that non-medical use increased with the increase in level of education. However,
the study determined life-time prevalence of NMUPD whereas other studies were based on past
year NMUPD. Students in the age group 18-20 years have been found to be at the highest risk of
non-medical use of prescription drugs than the others [38]. This could be because uneducated
people are unaware of the harm of prescription drug abuse and are less likely to perceive the risk
associated with them. Research has shown that college students who perceive prescription drugs
as less harmful are at higher risk of their non-medical use than the others [42, 43].
Marital status: Individuals who are married/cohabitating have been found to be at lower
risk of NMUPD, their abuse and dependence than those who were widowed/separated/divorced
or never married [5, 9, 36, 79, 80]. ‗Social Control Theory‘ suggests that strong bonds with
family, friends, school, work, religion and other aspects of the conventional society motivate
individuals to engage in responsible behavior and refrain from drug abuse and other health
behavior problems [89].
Employment: Review of the literature shows that employment has a protective
association with NMUPD [9]. Individuals who are unemployed have been found to have greater
probability of engaging in these behavioral problems when compared to those who were
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employed full time or part time [6, 7, 81]. This could be because employed individuals are
healthier than unemployed individuals and are thus, less likely to use and consequently, abuse
prescription drugs [72].
Income: In 1991, individuals with higher annual income were found to have greater odds
of NMUPD than those with lower annual family income [12]. However, analysis from the 199192 NLAES and 2001-02 NESARC, and more recent 2004-05 NESARC, reveals change in this
trend, and individuals with higher annual income have been found to be less likely to engage in
NMUPD than those with lower incomes [36, 80]. For example, individuals with annual income
less than $20,000 were more likely to engage in substance abuse, non-medical prescription drug
use, use of alcohol and inhalants compared to those with annual income of $75,000 or more [90].
The possible explanation can be that individual with lower income might be employed in high
risk conditions and therefore, take these drugs (simply for the experience or feeling that they
cause) to relieve stress and exhaustion caused by the work [60]. Another reason can be that
individuals with lower income are unemployed and thus, have more leisure time to engage in
these activities.
Health status: Individuals reporting poor/fair health status have been found to be more
likely to use prescription drugs non-medically, abuse them and/or become psychologically
dependent upon them when compared to individuals reporting good health [7, 9, 12, 91-93].
Use of tobacco: Individuals who use tobacco have been found to be more likely to
engage in NMUPD, their abuse and dependence when compared to those who do not use tobacco
[5, 7, 8, 46, 94, 95]. The results from these studies show that the individuals who use tobacco
have 1.3-9 times greater risk of using prescription drugs non-medically when compared to those
who do not use tobacco. The same was true for prescription drug abuse/dependence among the
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users of tobacco [96]. Interestingly, some studies also found that people indulging in NMUPD
were 5-7 times more likely to smoke as compared to those who did not engage in NMUPD [46,
97].
Use of alcohol: Use/abuse/dependence on alcohol is also a strong predictor of nonmedical use of prescription drugs. Past literature reports that individuals who use, abuse and
become dependent on alcohol have a greater probability of NMUPD, their abuse/dependence
when compared to those who do not use, abuse and become dependent on alcohol [5, 7, 8, 12,
36, 47, 93-95, 98-103]. But surprisingly, Becker and colleagues (2007, 2008) found that
individuals using/abusing/depending on alcohol were 50%-80% less likely to use prescription
drugs non-medically when compared to their counterparts [5, 7]. Some studies showed that
people indulging in NMUPD also had four times higher risk of binge drinking as compared to
those who did not engage in NMUPD [46, 97].
Use of illicit drugs: Individuals using illicit drugs have been found to be more likely to
use prescription drugs non-medically, abuse them or become dependent on them when compared
to those who did not use illicit drugs in the past year [5, 7, 8, 12, 13, 36, 47, 93-95, 98-103].
Furthermore, individuals using prescription drugs non-medically have been found to have 7-21
times greater probability of using illicit drugs as compared to those who did not engage in
NMUPD [11, 46]. The above literature review suggests that use of alcohol, tobacco and illicit
drugs can lead to NMUPD, its abuse/dependence and vice versa.

2.4

Predictors of substance use treatment services
Literature that has explored the relationship between socio-demographic factors and use

of substance abuse treatment services for prescription drug disorders is scarce.

29

Age: Becker et al. (2008) did not find any relationship between age and the probability of
seeking treatment for opioid use disorders though they found that probability of seeking
treatment decreases with age among the people with substance use disorders [6]. Results from
another study show that older people are more likely to use substance abuse treatment than the
younger people for alcohol abuse and dependence [61, 70].
Gender: Some researchers have found that women are less likely than men to receive
substance abuse treatment [60, 67] whereas other studies have found the opposite [70, 104, 105].
Race: Racial disparities have been observed in the probability of using substance abuse
treatment. In some studies, Whites have been found to be less likely to enter treatment [61, 106,
107] whereas, opposite results were found in other studies [60, 62, 67, 91, 108, 109]. This could
be due to the lack of perceived need for the use of drug abuse treatment. A study has found that
both Hispanics and Blacks are less likely to perceive the need for treatment of prescription drug
use disorders than the other races [108]. Low perceived need could lead to lower use of
substance abuse services among Hispanics and Blacks [110-112].
Education: Some studies indicate that individuals with lower education are less likely to
enter treatment [61, 105], whereas other studies suggest that people with lower education are
more likely to enter treatment than those having higher education [70, 104].
Marital status: A study conducted by Wu et al. (2003) suggests there is no relationship
between marital status and odds of seeking substance abuse treatment among substance abusers.
Employment: Employment has been found to be negatively correlated with the
likelihood of use of substance abuse services. Unemployed individuals have been found to be
more likely to complete drug abuse treatment than those who are either employed in a part-time
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or full-time job [6, 70]. As mentioned previously, employed individuals might not want their
employer to know about their use of substance abuse treatment or they might be unaware that
their health insurance covers substance abuse treatment. This explanation is supported by the
finding of Jean Oggins (2003) who found that 25%-38% of the employees who used substance
use services did not know their health insurance covered substance use treatment [74, 75].
Income: Income has been found to have a positive relationship with the probability of
seeking substance abuse treatment. People with higher income have been found to be more likely
to use substance abuse treatment services than those with lower income [113-115]. The possible
justification could be that lower income individuals usually have lower health coverage which
might limit their use of substance abuse services as research has shown that people without
health insurance are less likely to use and complete treatment services than those with health
insurance [17, 64, 67].
Health status: There is not any study that has looked at the relationship between health
status and likelihood of seeking substance abuse services for prescription drug disorders.
Illicit drugs: Individuals using either prescription drugs non-medically, illicit drugs or
both have been found to be more likely to use substance abuse services when compared to those
who did not misuse prescription drugs or both prescription drugs and illicit drugs in the past year
(Wu et al., 2003).

2.5

Summary of literature review
Uninsured individuals have found be more likely to use prescription drugs non-medically

although the relationship between health insurance and prescription drug abuse and dependence
is not clear. Risk of prescription drug abuse and dependence has been found to differ by type of
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health coverage, and individuals with Medicaid coverage have been found to be more likely to
indulge in prescription drug abuse and dependence when compared to the other groups.
The review of the literature suggests mixed impact of health insurance on use of
treatment services among substance abusers. In two out of five studies, uninsured individuals
were more likely to use substance abuse services. Additionally, among the insured, use of
substance use services has been found to differ by type of health coverage, and individuals with
Medicaid and other public programs have been found to be more likely to use treatment services.
Other demographic and economic factors have also been observed to be important
predictors of NMUPD, their abuse and dependence, and use of treatment services. Younger
individuals have been found to be at higher risk of NMUPD, their abuse and dependence, but
older individuals have been found to more likely to use substance abuse treatment for these
problems. Gender and race have been found to have a mixed association with NMUPD, their
abuse and dependence, and use of substance abuse treatment. Individuals with some college
education have been found to be at lower risk of NMUPD, drug abuse and dependence, but the
relationship between education and substance abuse treatment is not clear. Marriage and
employment were found to have a protective relationship with NMUPD, prescription drug abuse
and dependence. The existing literature did not suggest any association between marital status
and use of substance abuse services. But employed individuals have been found to be less likely
to use substance abuse treatment than unemployed individuals. Previous literature suggests
mixed association between family income and NMUPD although individuals with higher family
income have been found to be more likely to use substance abuse treatment for NMUPD, their
abuse and dependence than those having lower family income. People with poor/fair health
status have been observed to be more likely to engage in NMUPD, abuse and dependence but the
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relationship between health status and the use of substance abuse treatment has not been
examined for these health behavior problems. Use of alcohol, tobacco and illicit drug has been
found to lead to NMUPD, its abuse/dependence and vice versa. The impact of the use of alcohol,
and tobacco on the use of substance abuse treatment has not been investigated but individuals
using illicit drugs have been found to be more likely to use substance abuse treatment than their
counterparts.
Largely, the relationship between socio-demographic and economic factors and NMUPD,
their abuse/dependence is unclear. Although health insurance has been found to be an important
predictor of these health problems, its effect on different sub groups of population has not been
studied. It is important to study the effect of health insurance and different demographic factors
on these health problems because health insurance is amenable to policy change. This
investigation can help identify various high risk groups (with and without health insurance) who
should be focused while implementing health policy changes and developing prevention and
treatment programs. Table 5 presents list of studies finding positive relationship between the
NMUPD, their abuse and dependence. Table 6 presents list of studies finding negative
relationship between the NMUPD, their abuse and dependence. Summary of the review of
literature is also been presented in Table 7.
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Table 5: Studies finding positive relationship between the independent and dependent variables
Positive relationship

Dependent variables

Independent variables

NMUPD

Health insurance (insured)

-

Prescription drug abuse and
dependence
Becker et al., 2008

Age

Simoni-Wastila, et al., 2004
Simoni-Wastila, L., &
Strickler, G., 2004
Wu et al., 2008

Simoni-Wastila, L., & Strickler, G.,
2004
Becker et al., 2007
Carise et al., 2007

Gender (male)

Wu et al., 2003
McCabe et al., 2004
McCabe et al., 2005
Huang et al., 2006
Kroutil et al., 2006
McCabe et al., 2007
Huang et al., 2006
Becker et al., 2007
Compton et al., 2007

Huang et al., 2006
Carise et al., 2007
Compton et al., 2007

Weisner et al., 2002

Wu et al., 2008
Huang et al., 2006

Weisner et al., 2002
Keyes et al., 2008
Perron et al., 2009

Race and ethnicity (other than
Whites)

Level of education

Huang et al., 2006

Weisner et al., 2002
Wu et al., 2005
Weisner et al., 2002

Marital status (married)
Simoni-Wastila, L., &
Strickler, G., 2004
Becker et al., 2007
Becker et al., 2008
Simoni-Wastila, et al., 2004

Simoni-Wastila, L., & Strickler, G.,
2004
Becker et al., 2008

Health status (fair /poor)

Simoni-Wastila, L., &
Strickler, G., 2004
Simoni-Wastila, et al., 2004
Matzger and Weisner., 2007

Simoni-Wastila, L., & Strickler, G.,
2004
Becker et al., 2008
Wu et al., 2008

Tobacco use/abuse/dependence

McCabe et al., 2005

Compton et al., 2007

Employment status (unemployed)

Family income

Use of substance abuse
treatment
Waehrer et al., 2008
Weaver et al., 2008
Weisner et al., 2002
Wu et al., 2003

Wu et al., 2003
Becker et al., 2008

S Green-Hennessy, 2000,
Mertens & Weisner, 2000,
Pollack & Reuter, 2006.

34

Positive relationship
Independent variables

Alcohol use/abuse/dependence

Illicit drugs use/abuse/dependence

Dependent variables
NMUPD

Prescription drug abuse and
dependence

McCabe et al., 2005
Boyd et al., 2006
Becker et al., 2007
Tetrault et al., 2008
Becker et al., 2008
Simoni-Wastila, L., &
Strickler, G., 2004
Simoni-Wastila, et al., 2004
McCabe et al., 2005
McCabe et al., 2005
Boyd et al., 2006
Ives et al., 2006
Stahl et al., 2006
McCabe et al., 2006
McCabe et al., 2007
Novak et al., 2007
Becker et al., 2007
Blanco et al., 2007
Tetrault et al., 2007
Becker et al., 2008
Simoni-Wastila, et al., 2008
Matzger and Weisner., 2007
Herman-Stahl et al., 2007
Simoni-Wastila, et al., 2004
McCabe et al., 2005
McCabe et al., 2005
McCabe et al., 2005
Boyd et al., 2006
Ives et al., 2006
Pletcher et al., 2006
Stahl et al., 2006
Becker et al., 2007
Blanco et al., 2007
Herman-Stahl et al., 2007
Matzger and Weisner., 2007
Novak et al., 2007

Use of substance abuse
treatment

Simoni-Wastila, L., & Strickler, G.,
2004
Blanco et al., 2007
Carise et al., 2007
Compton et al., 2007
McCabe et al., 2007
Becker et al., 2007
Wu et al., 2008

Blanco et al., 2007
Becker et al., 2008
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Wu et al., 2003

Positive relationship
Independent variables

Dependent variables
NMUPD

Prescription drug abuse and
dependence

Tetrault et al., 2007
Becker et al., 2008
Simoni-Wastila, et al., 2008
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Use of substance abuse
treatment

Table 6: Studies finding negative relationship between the independent and dependent variables
Negative relationship

Dependent variables

Independent variable

NMUPD

Prescription drug abuse and
dependence

Use of substance abuse
treatment

Health insurance (insured)

Kroutil et al., 2006
Becker et al., 2007
Tetrault et al., 2007
Simoni-Wastila, et al., 2004
Simoni-Wastila, L., & Strickler,
G., 2004
Huang et al., 2006
Ives et al., 2006
Johnston et al., 2006
Kroutil et al., 2006
Becker et al., 2007
Blanco et al., 2007
Becker et al., 2008
Simoni-Wastila, et al., 2004
Simoni-Wastila, L., & Strickler,
G., 2004
Boyd et al., 2006
Stahl et al., 2006
Blanco et al., 2007
Simoni-Wastila, et al., 2008
McCabe et al., 2003
McCabe et al., 2004
Simoni-Wastila, et al., 2004
Simoni-Wastila, L., & Strickler,
G., 2004
McCabe et al., 2005
McCabe, Boyd, & Teter., 2005
Huang et al., 2006
Kroutil et al., 2006
Stahl et al., 2006
Blanco et al., 2007
McCabe et al., 2007
Herman-Stahl et al., 2007
Simoni-Wastila, et al., 2008

Becker et al., 2008

Wu et al., 2003

Miller et al., 2004
Huang et al., 2006
Blanco et al., 2007
Compton et al., 2007
Kaloyanides et al., 2007
McCabe et al., 2007
Wu et al., 2008

Waehrer et al., 2008
Becker et al., 2008

Miller et al., 2004
Simoni-Wastila, L., & Strickler,
G., 2004
Compton et al., 2007
Wu et al., 2008
Becker et al., 2008
Simoni-Wastila, et al., 2008
Miller et al., 2004
Carise et al., 2007
Simoni-Wastila, et al., 2008

Waehrer et al., 2008
Wu et al., 2005

Age

Gender (male)

Race and ethnicity (other than
Whites)
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Wells et al., 2001
Wu et al., 2003
Wu, Ringwalt & William, 2003
Wu et al., 2005
Wu et al., 2007
Waehrer et al., 2008
Weaver et al., 2008

Negative relationship

Dependent variables

Independent variable

NMUPD

Prescription drug abuse and
dependence

Use of substance abuse
treatment

Level of education

McCabe et al., 2004
Blanco et al., 2007
Becker et al., 2008
Durell et al., 2008

Becker et al., 2007
Blanco et al., 2007

Wu et al., 2003
Wu et al., 2005
Waehrer et al., 2008

Marital status (married)

Simoni-Wastila, et al., 2004
Huang et al., 2006
Becker et al., 2007
Blanco et al., 2007

Simoni-Wastila, L., & Strickler,
G., 2004
Huang et al., 2006
Blanco et al., 2007
Becker et al., 2007
Compton et al., 2007
Carise et al., 2007

Huang et al., 2006
Blanco et al., 2007
Kroutil et al., 2006
Simoni-Wastila, et al., 2008

Compton et al., 2007

Employment status
(unemployed)
Family income

Health status (fair /poor)

Simoni-Wastila, et al., 2008

Tobacco use/abuse/dependence
Becker et al., 2007
Becker et al., 2008
Simoni-Wastila, L., & Strickler,
G., 2004

Alcohol use/abuse/dependence
Illicit drugs
use/abuse/dependence
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Wu et al., 2003
Waehrer et al., 2008

Table 7: Summary of literature review
Greater probability of
Independent variables

NMUPD

Health insurance status

Uninsured individuals

Use of substance abuse
treatment
Mixed effect

Medicaid

Age

Younger individuals

Younger individuals

Medicaid/other public
insurance
Older individuals

Gender

Mixed effect

Mixed effect

Mixed effect

Race and ethnicity

Mixed effect

Mixed effect

Mixed effect

Level of education

Lower education

Lower education

Mixed effect

Marital status

Unmarried individuals

Unmarried individuals

No effect

Employment status

Unemployed individuals

Unemployed individuals

Unemployed individuals

Family income

Mixed effect

Health status

Poor/fair health

Poor/fair health

Use of tobacco

Users of tobacco

Users of tobacco

Users of tobacco

Use of alcohol

Users of alcohol

Users of alcohol

Users of alcohol

Use of illicit drugs

Users of illicit drugs

Users of illicit drugs

Users of illicit drugs

Type of health insurance

-

Prescription drug abuse
and dependence
-

-

39

Higher income
-

CHAPTER 3: METHODOLOGY
This chapter provides a description of the method, which includes: 1) research design, 2)
description of the dataset, 3) description of the study sample, 4) independent and dependent
variables, 5) data analysis, 6) regression diagnostics, 7) interpretation of the odds ratio in case of
interaction between two independent variables.
3.1

Research design and data
This is a retrospective cross-sectional study design. The study used the 2007 National

Survey on Drug Use and Health (NSDUH) data. NSDUH is sponsored by the Substance Abuse
and Mental Health Services Administration (SAMHSA), and data is collected by the Research
Triangle Institute (RTI) International. NSDUH provides estimates of substance use and related
disorders for the U.S. general population. The purpose of NSDUH is to determine changes in the
pattern of use of tobacco, alcohol and other drugs with time, their consequences on individuals‘
health and to identify individuals who are at high risk for substance use and abuse. Precisely,
NSDUH collects nationwide information on the prevalence, patterns and consequences of the use
of alcohol, tobacco and nine categories of illicit and prescription drugs in the general U.S.
civilian non-institutionalized population aged 12 years and older. Drugs included in this survey
are illicit drugs such as marijuana, cocaine, crack, heroin, hallucinogens, inhalants and four
categories of prescription drugs such as pain relievers, tranquilizers, stimulants and sedatives
[116]. The data also collects other information such as socio-demographic characteristics and the
mental health of the individuals.
NSDUH makes use of multistage area probability sampling methods to select a
representative sample in all 50 states. Data are collected from household residents, residents of
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shelters, rooming or boarding houses, halfway houses, college dormitories, group homes and
civilians residing on military bases. Individuals from the age groups 12–17, 18–25 and 26 years
and older are oversampled to create equal sample sizes to improve the precision of drug use
estimates for these key subgroups. One or two residents of a household are selected by the field
interviewer through an in-person interview. Once selected, participation by a respondent is
voluntary. Those individuals, who agree to participate, complete an interview on a laptop in their
home. Participants are assured that their names will not be recorded and that their responses will
be kept confidential. All study procedures and protections are carefully explained to them. For
adolescents aged 12–17 years, the field interviewer first seeks verbal consent from their parents
or guardians. After obtaining parental permission, field interviewer approaches the adolescents to
obtain their agreement to participate in the study. Parents are then asked to leave the interview
setting to ensure the confidentiality of their children‘s responses. The interview takes about one
hour, and at the completion of the interview respondent receives an incentive of $30 for their
participation. Details of NSDUH are described elsewhere [117].
3.1.1 Reliability and validity of NSDUH:
The NSDUH survey items have been evaluated for accuracy and reproducibility of results
[26]. The survey has been refined several times since its initiation. NSDUH being a survey is
prone to non-response bias and social desirability bias. Non-response bias occurs when sampling
units selected for the survey are either unable to provide responses or are unable to participate in
the survey. This leads to a situation where respondents are different from non-respondents [118].
In 2007 NSDUH, non-response-adjusted and post stratified analysis weights were used to
calculate unbiased estimates of drug use. Survey administrators try to minimize non-response
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bias by providing a $30 incentive to the respondents. Missing or inconsistent responses are
resolved where possible through a logical editing process, or they are imputed using statistical
methodology. These imputation procedures are based on responses to multiple questions. Thus,
the maximum amount of information possible is used in determining whether a respondent is a
user or nonuser.
Social desirability bias, also known as self report bias takes place when individuals
provide socially acceptable responses to questions. This causes under-reporting of behaviors
deemed unacceptable by society and over-reporting of behaviors acceptable in society [119].
This occurs due to either social stigma or fears of disclosure. ACASI (Audio Computer Assisted
Self Interview) technology has been used in the NSDUH since 1999. This technology was also
used in the 2007 NSDUH and helps to control social desirability bias. In this method, questions
that involve sharing of private, confidential and sensitive information are administered using a
computer, and participants read the questions on a computer screen or listen to them through
headphones and then enter their responses into the computer. This encourages privacy and makes
respondents comfortable in providing information regarding illicit drug use and other sensitive
behaviors. Moreover, respondents are assured that their responses will be kept confidential.
These measures have been found to be effective in reducing reporting bias [120]
A study was conducted to determine the reliability of the responses provided by the
respondents in NSDUH. The study used an interview/re-interview method and 3,136 individuals
were interviewed on two occasions during 2006 at a gap of five to fifteen days. The reliability of
the responses was assessed by comparing the responses of the first interview to the responses
from the re-interview. Results showed that respondents provided consistent answers on the
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substance use and mental health measures [27]. Jordan and coworkers (2008) conducted a
clinical validation study to determine the validity of the estimates of substance use disorder
(SUDs) obtained from the NSDUH. SUDs in this study also included abuse or dependence on
prescription drugs. The sample consisted of 288 adults and adolescents recruited from the
community and outpatient substance abuse treatment programs in North Carolina. They used the
Structured Clinical Interview for DSM-IV (SCID-IV) for adults and the Pittsburgh Adolescent
Alcohol Research Center's Structured Clinical Interview (PAARC-SCID) for adolescents to
calculate the validity of the NSDUH questions in measuring SUDs. Kappa value for any drug
abuse, dependence or drug abuse/dependence varied from 0.59-0.74, which indicates fair to
moderate level of agreement between the NSDUH and the SCID/PAARC-SCID interviews
[121].
A recent study was conducted by SAMHSA and NIDA, which examined the validity of
self-reported data of NSDUH on drug use among persons aged 12-25 years. This study compared
self-reported data with the results of drug tests obtained from urine and hair specimens of the
same respondents who provided the self-reported data. The results of the study showed that most
of the people in that age group accurately reported their drug use [122].

3.2

Sample Selection
2007 NSDUH survey had a sample size of 67,870 persons. However, before making the

file public; micro agglomeration, substitution, sub-sampling and calibration (MASSC) method
was used to control the risk of disclosing the identity of any respondent. This method involves
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removing variables that presented higher risk of identifying the respondents and collapsing the
values of other variables. Some of the records were also randomly sampled and removed from
the original file. Additionally, substitution of the data was done to maintain confidentially of the
responses and the resulting data were checked for any effect on the level and accuracy of
estimates. As a result of the MASSC method, only 55,435 records are available on the public
use file.
Inclusion criteria:
Individuals who were 12-64 years old and non-institutionalized were considered for the
analysis.
Exclusion criteria:
Individuals receiving health coverage through Medicare and ‗other‘ health insurance
programs were excluded from the analysis. Medicare enrollees were excluded from the analysis
because most of them were elderly individuals (65 years and older) who had health coverage.
Thus, there was no variability in health coverage among this age group. They were also different
from the rest of the population in other socio-demographic and economic characteristics such as
income, employment etc.
Individuals with ‗other‘ health insurance were excluded from the analysis because this
group included individuals who had health insurance, but did not know what kind of health
insurance they had. Use of this group would have contaminated the sample and might have
biased the study results.
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3.3

Sample size calculation
For sample size calculations, alpha = 0.05, and power = 0.80 were used in this study.

Other required estimates such as baseline probability (probability of NMU/ prescription drug
abuse/ dependence among the uninsured), percentage of people having health insurance among
those who engage in these problem health behaviors and odds ratio were obtained from the
literature.
Effect size:
The effect size calculation was based on the primary objective of this study, which was to
assess the relationship between health insurance and other socio-demographic factors on
NMUPD, their abuse and dependence. Correlation coefficients were used to state the relationship
between health insurance coverage and other independent variables such age, gender, race and
ethnicity, type of education, marital status, employment, family income, health status, use of
tobacco and use of alcohol.
Correlation coefficient is a measure of correlation between two variables. For the sample
size calculation, correlation between two independent variables was used. Review of the
literature suggested that it lie in the range of - 0.36 to less than 0.60 [8, 71]. A conservative effect
size of r = - 0.36 (r2=0.13) was used for sample size calculations.

Other estimates used for calculation of NMUPD, prescription drug abuse and dependence, and
substance abuse treatment:
Besides effect size, other estimates were used for the calculation of sample size. These
include baseline probability (probability of NMU/prescription drug abuse/dependence among the
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uninsured), percentage of people having health insurance among those who engage in these
problem health behaviors, and odds ratio. These parameters are presented in Table 8.
Table 8: Parameters required for sample size calculation
Parameter

For NMUPD

For prescription drugs
abuse or dependence

For utilization of
substance abuse
services

Baseline probability

4.5% to 8.2%

2.0% to 13.8%

1.6% to 12.6%

[5, 7, 91]

[5-7]

[6, 62, 105]

Percentage of people having health
insurance among those who engage
in the respective problem health
behavior

80.6% to 91.4%

62.20% to 85.80%

84%

[5, 7, 91]

[5-7]

[6]

Odds ratio

1.2 to 1.7

1.4 – 3.2

0.5 to 4.9

[5, 7, 60]

[5-7, 62]

[62, 105]

For NMUPD:
Baseline probability = 4.5% (0.045), odds ratio =1.2, and percentage of those having
health insurance= 80.6% were used for this study.
For prescription drugs abuse or dependence:
Sample size calculations were performed using the following parameters: baseline
probability = 2.0% (0.020); odds ratio =1.4 and percentage of those having health insurance=
62.20%.
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For utilization of substance abuse services:
Employing a more conservative approach, baseline probability = 1.6% (0.016), odds ratio
=0.5, and percentage of those having health insurance= 84% were used for the calculation of
sample size.
Estimated sample size:
By using logistic regression analysis and an effect size (r2) = 0.13, power = 80%,
significance level of 0.05, and the above mentioned parameters; the most conservative sample
size required to detect minimum detectable odds ratio would be: 37,956 for ‗NMUPD‘, 12,635
for ‗prescription drug abuse and dependence‘, and 2,956 for ‗substance abuse services‘.
NCSS/PASS software was used for the sample size calculations [123]. Preliminary analyses
indicated that the required sample size was available from the 2007 NSDUH.
All of the respondents in the 2007 NSDUH were considered for the analysis of NMUPD.
Individuals who had used at least one prescription drug non-medically in the past year were
considered for the analysis of prescription drug abuse and dependence. In 2007 NSDUH,
questions regarding use of substance abuse treatment were asked only to those individuals who
reported non-medical use of prescription/illicit drugs ever in their life. However, for this study,
the sample was limited to those individuals who reported non-medical use of prescription drugs
or both prescription drugs and illicit drugs ever in their life.
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3.4

Definition of dependent variables

Non-medical use:
It was defined as a binary variable where one refers to non-medical use of at least one
medication (in the past year) from the pain relievers, tranquilizers, stimulants or sedatives class
without a prescription or the use of medication that had occurred simply for the experience or
feeling that it cause, and individuals who did not meet the above criteria were assigned zero.
Prescription drug abuse or dependence:
Prescription drug abuse was defined as a binary variable where one refers to the
abuse/dependence on psychotherapeutic drugs in the past year, and zero refers to absence of such
an abuse/dependence in the past year.

Use of substance use services:
Individuals‘ use of substance use treatment services were determined from the following
question: ―During the past 12 months, when you received treatment, was the treatment for
alcohol use only, drug use only, or both alcohol and drug use?‖ The term ‗drug‘ in this question
includes marijuana, cocaine, heroin, hallucinogens, inhalants, methamphetamine or lifetime use
of prescription pain relievers, tranquilizers, stimulants, or sedatives. Individuals were considered
as having received treatment if they received treatment for drugs, for both drugs and alcohol, for
alcohol only (but last treatment was also for drugs), drugs only (but the last treatment was also
for alcohol).
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3.5

Definition of independent variables
Based on the review of literature, the following independent variables were used for the

analysis: health insurance status, age, gender, race/ethnicity, type of education, marital status,
employment, family income, health status, use of tobacco and use of alcohol.
Health insurance coverage:
Individuals were classified into three health insurance categories: private; public (having
Medicaid/S-CHIP, Tricare, Champus, Champva , VA, military insurance or any other type of
public health insurance); and uninsured.
Other Independent variables:
Based on the previous literature, different demographic variables were categorized as age
(aged 12-17, 18-25, 26-34, 35-49 and 50-64 years); sex; race/ethnicity (categorized as nonHispanic white, non-Hispanic black, Hispanic and other); years of schooling categorized as less
than high school, high school graduate, some college and college graduate); marital status
(categorized as married, widowed/divorced/separated and never been married); employment
status was classified as employed, unemployed or not in labor force; income (categorized as less
than 20,000, 20,000-39,999, 40,000-74,999 and 75,000 or above); reported general health
(categorized as excellent/very good/good and fair/poor); use of tobacco (yes/no) and use of
alcohol (yes/no).
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3.6

Data analysis
Data analysis were conducted using SAS® statistical software version 9.1 [124].

Bivariate association between demographic factors and dependent variables were determined
through chi square test for categorical variables. All the independent variables in bivariate
analyses were tested for significance at p<0.05. Multivariate logistic regression analysis was
used to determine the relationship between dichotomous or binary dependent variables and one
or more independent variables. It predicts the odds of the occurrence of an event (i.e., dependent
variable). For this study, the following Logistic regression model was used.
Logit [P (Y=1)] = βo + β1 (insur) + β2 (age) + β3 (gender) + β4 (race) + β5 (edu-type) + β6
(marital status) + β7 (employ) + β8 (income) + β9 (health status) + β10 (tobacco use) + β11
(alcohol use)

+ β12 (insur × age) + β13 (insur × gender) + β14 (insur × race) + β15 (insur ×

edu-type) + β16 (insur × marital status) + β17 (insur × employ) + β18 (insur × income) + β19 (
insur × health status ) + β110 (insur × tobacco use) + β111 (insur × alcohol use) + ε
Where Y denotes dependent variable (i.e., NMUPD, abuse or use of substance use services).
βo is the intercept.
β1 denotes the logistic regression coefficients for health insurance.
Insur denotes type of health insurance.
β12 indicates the logistic regression coefficient for interaction between health insurance and age.
ε indicates the error term.
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3.6.1 Sample weights:
The study data for the 2007 NSDUH is obtained through multistage area probability
sampling. This means estimates obtained from the 2007 NSDUH are based on sample survey and
information is not collected from the entire U.S. population. Thus, to get unbiased estimates of
the drug misuse, sample weights provided by the survey were used for the analyses. Use of
weights helps to account for the complex sampling methodology and for non-response in the
NSDUH. Sampling weights also normalized the data to the distributions based on the 2000
census.
3.6.2 Model fit
Several measures of model fitness were assessed. Logistic regression analysis predicts the
probability of a binary outcome. In assessing model fitness, the objective is to compare the
observed outcome with the expected outcome. If the model can accurately predict those with and
without the outcome, then the model is considered to be robust.
Goodness of fit of the model:
Goodness of fit of the model describes how well the model fits the data. It can be
measured by the Hosmer and Lemeshow chi-square test of goodness of fit or R square. The
Hosmer and Lemeshow chi-square test of goodness of fit tests the null hypothesis that there is no
difference between the observed and predicted values of the outcome variable. This test divides
the observations into 10 equal sized groups (deciles) based on the predicted probabilities. The
test statistics follows a chi square distribution, and if the results of this test are non-significant,
then one cannot reject the null hypothesis. This means there is no difference between the
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observed and predicted values of the outcome variable, which suggests that the selected model
adequately describes the outcome of the study [125, 126].
R square:
It is also known as coefficient of determination. It does not measure the goodness of fit of
the model but explains how much variability in the outcome variable is accounted for by the
statistical model used for the analysis. Thus, it indicates usefulness of the model in explaining
the outcome variable. It is regarded as the measure of effect size.
Nagelkerke's R2 will be used in this study. It‘s an adjustment of the Cox & Snell's R2 and
its value varies from zero to one. Zero denotes that independent variables do not explain the
outcome variable, and one denotes that they perfectly explain the outcome [125, 126].
Percent concordant:
The percent concordant values provide an indication of overall model quality through the
association of predicted probabilities and observed responses. These values are based on the
maximum likelihood estimation of the percent of paired observations of which values differ from
the response variable [127]. A pair of observations with different observed responses is said to be
concordant if the observation with the lower ordered response value (for e.g. nmu = 0) has a
lower predicted mean score than the observation with the higher ordered response value (nmu =
1). Thus, the higher the predicted event probability of the higher response variable, the greater
will be the value of the percent concordant. The literature does not provide any range of values
for percent concordant to check for the goodness of the model.
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Model discrimination
Area Under the Receiver Operating Characteristics Curve (AUROC) compares expected
predicted probability with the observed outcome and compares if the model was able to
accurately distinguish those with and without the outcome. An area of one indicates that the test
correctly distinguishes between those with and without the outcome whereas an area of 0.5 or
less suggests that the model may not have been appropriate [125, 126].
Test for interaction effects:
The likelihood ratio test (LRT) was performed to assess the importance of interaction
terms. LRT for a particular parameter compares the likelihood of obtaining the data when the
parameter is zero with the likelihood of obtaining the data when the parameter is not zero. The
LRT is used only when a simple model is nested within the more complex model, i.e. complex
model must differ from the simple model only by the addition of one or more parameters. The
test follows a chi square distribution. If the p value of the test is less than 0.05, this suggests that
the parameter contributes to the model and should be retained in the model [125, 126].
In this study, joint test of significance was used. It is a type of LRT where all the
interaction terms to be tested are entered into the model all at once. If the overall model is
significant, this means there are some interaction terms that contribute significantly to the model.
The next step is to obtain the reduced model by dropping the insignificant interaction term. The
joint test of significance is conducted again for the reduced model, and if the result of test is
significant, this suggests that interaction terms in the reduced model contribute significantly to
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the overall model and should be retained in the model. The final model used for the analysis is
the model from which all the insignificant interaction terms have been dropped.

3.7

Human subjects’ approval
The study was submitted to the University of New Mexico Health Science Center Human

Research Review (HRRC) committee for an exempt review because this study involves use of
publicly available existing data from which all the identifiers have been removed before making
the data public. The study was approved for exempt review by the HRRC committee.
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CHAPTER 4: RESULTS
This chapter presents results of the study and has three sections. Section-I describes
association between health insurance coverage and non-medical use of prescription. Section-II
describes the relationship between health insurance and prescription drug abuse/dependence.
Section-III presents association between health coverage and use of substance abuse treatment
year among those who reported non-medical use of prescription drugs in their life.
4.1

Association between health insurance and NMUPD

4.1.1 Descriptive statistics by health insurance
Table 9 presents the descriptive statistics of the study sample. The sample consisted of
52,530 respondents out of which 82% had health insurance. Sixty nine percent had private health
insurance, and 13% had public health insurance. Eight percent of the population reported
NMUPD. NMUPD was highest among uninsured individuals and lowest among individuals with
private health coverage. Uninsured individual were also found to have greater use of tobacco
(49%) and illicit drugs (23%) whereas use of alcohol was higher among individuals with private
health coverage (69%).
Private health insurance was common among 35-49 year old individuals (33%), Whites
(74%), college graduates (32%), married (59%), employed (83%), those with higher family
income greater than $75,000 (45%), and among individuals with excellent/very good/good health
(94%). On the other hand, individuals with public health coverage were mostly females (57%),
and 12-17 year old (27%). They were more likely to have never been married (47%), have lower
education (47%) and family income (43%). Around one-fifth of the respondents did not have
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health coverage and they were generally males (54%), had either less than high school (35%) or
high school education (35%), were never been married (44%) and reported $20,000-$40,000 as
the family income (34%).
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Table 9: Characteristics of the sample by health insurance categories (Weighted %)
Variable category
Gender
Male
Female
Age
12-17
18-25
26-34
35-49
50-64
Race
White, non-Hispanic
Black, non-Hispanic
Hispanics
Others
Education
Less than high school
High school graduate
Some college
College graduate
Marital status
Married
Widowed/ divorced/separated
Never been married
Employment status
Employed
Unemployed
Other
Annual household income
< $20, 000
$20, 000-$39,999

Total sample

Private
insurance

Public
insurance

Uninsured

P-value

49.39
50.61

49.52
50.48

43.55
56.45

53.58
46.42

<0.0001

12.11
15.70
16.87
30.73
24.58

11.10
12.88
15.59
33.10
27.33

26.74
18.03
14.43
20.08
20.72

5.49
23.92
23.25
30.17
17.18

<0.0001

66.01
12.06
15.40
6.52

73.91
9.38
10.28
6.43

48.44
24.78
20.02
6.76

50.30
13.05
30.92
5.73

<0.0001

24.73
26.19
23.97
25.11

17.54
23.95
25.87
32.64

47.29
26.45
19.10
7.16

35.34
35.15
20.05
9.46

<0.0001

51.53
14.46
34.01

59.44
11.83
28.73

33.78
18.95
47.27

34.60
21.31
44.08

<0.0001

75.63
4.33
20.04

82.63
2.25
15.40

46.35
8.27
45.39

69.87
9.64
20.49

<0.0001

16.22
19.96

6.48
14.87

43.29
26.48

32.72
34.09

<0.0001
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Variable category
$40, 000-$74,999
≥ $75,000
Reported general health
Excellent/very good/good
Fair/poor
Past year use of tobacco
Yes
No
Past year use of alcohol
Yes
No
Past year use of illicit drugs
Yes
No
NMU
Yes
No
Rx drug abuse/dependence
Yes
No
Treatment
Yes
No
Total Observation

Total sample
29.94
33.88

Private
insurance
33.88
44.77

Public
insurance
18.63
11.60

Uninsured

P-value

23.73
9.47

90.80
9.20

94.08
5.92

82.08
17.92

85.17
14.83

<0.0001

36.97
63.03

33.38
66.62

39.72
60.28

48.58
51.42

<0.0001

68.79
31.21

72.83
27.17

52.95
47.05

65.39
34.61

<0.0001

16.60
83.40

14.39
85.61

19.10
80.90

22.84
77.16

<0.0001

7.51
92.49

6.46
93.54

8.41
91.59

10.66
89.34

<0.0001

0.97
99.03

0.64
99.36

1.45
98.55

1.84
98.16

<0.0001

5.60
94.40
52530

3.43
96.57
31939 (69.16%)

7.09
92.91
9668 (12.93%)

9.33
90.67
9407 (17.91%)

<0.0001
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4.1.2 Descriptive statistics by NMUPD
Table 10 presents descriptive statistics for those who engaged in NMUPD compared to
those who did not engage in NMUPD in the past year. Out of the total sample, 5190 (10%)
individuals reported NMUPD. About three-fourths of the people using prescription drugs nonmedically were insured and about 13% of the non-medical users of prescription drugs also
abused or were dependent on prescription drugs. Use of tobacco (68%), alcohol (87%), and illicit
drugs (100%) was considerably higher among non-medical users compared to those who
abstained from NMUPD. More than 70% of the non-medical users received treatment for
NMUPD, illicit drug use, and abuse or dependence on prescription and illicit drugs.
Prevalence of NMUPD was higher among males (53%) and younger adults aged 18-25
year old (32%). Whites (75%) had significantly greater non-medical use of prescription drugs
followed by Hispanics (12%), Blacks (8%) and others (5%). People engaging in NMUPD were
also more likely to have less than a high school education (29%), had never been married (55%)
and were employed (72%). The number of people using prescription drugs non-medically
increased with the increasing income and it was highest in the income category $40,000-$74,999.
Table 10: Characteristics of the non-medical users of prescription drugs (weighted %)
Variable category
Health insurance
Insured
Uninsured
Gender
Male
Female
Age
12-17
18-25
26-34
35-49

NMUPD

Absence of NMUPD

P - value

74.42
25.58

82.71
17.29

<0.0001

52.94
47.06

49.10
50.90

0.0002

13.00
31.96
19.50
23.82

12.04
14.39
16.66
31.29

<0.0001
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Variable category
50-64
Race
White, non-Hispanic
Black, non-Hispanic
Hispanics
Others
Education
Less than high school
High school graduate
Some college
College graduate
Marital status
Married
Widowed/divorced/separated
Never been married
Employment status
Employed
Unemployed
Other
Annual household income
< $20, 000
$20, 000-$39,999
$40, 000-$74,999
≥ $75,000
Reported general health
Excellent/very good/good
Fair/poor
Past year use of tobacco
Yes
No
Past year use of alcohol
Yes
No
Past year use of illicit drugs
Yes
No
Rx drug abuse/dependence
Yes
No
Treatment
Yes
No
Total Observation

NMUPD
11.72

Absence of NMUPD
25.62

P - value

75.05
8.32
11.86
4.76

65.28
12.37
15.69
6.67

<0.0001

28.70
27.36
26.44
17.49

24.40
26.10
23.77
25.73

<0.0001

30.89
13.72
55.39

53.25
14.52
32.22

<0.0001

72.35
7.34
20.31

75.90
4.08
20.01

<0.0001

22.33
22.56
28.85
26.26

15.72
19.75
30.03
34.50

<0.0001

89.88
10.12

90.88
9.12

<0.0001

68.16
31.84

34.44
32.72

<0.0001

87.32
12.68

67.28
32.72

<0.0001

99.76
0.24

9.85
90.15

<0.0001

12.97
87.03

100.00

<0.0001

72.62
27.38
5190 (9.88%)

3.40
96.60
47340 (90.12%)

<0.0001
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4.1.3 Prevalence of NMUPD by different therapeutic classes:
Figure 1 shows prevalence of NMUPD by therapeutic class. Non-medical use was
highest for pain relievers (76%) followed by tranquilizers (29%), stimulants (19%) and sedatives
(5%). Table 11 presents non-medical use of the top five drugs within each therapeutic class.
Among different pain relievers, Vicodin/Lortab/Lorcet was used most frequently non-medically
(9%), whereas codeine was used the least (4%). Among different types of tranquilizers, most of
the respondents reported using Valium/Diazepam (6%) non-medically followed by Xanax (5%),
Klonopin (2%), Soma (1%) and Flexeril (1%). Most of the individuals using prescription
stimulants non-medically reported non-medical use of methamphetamine/Desoxyn/Methedrine
(5%) and some of them also used Dextroamphetamine (0.2%). In the list comprising the top five
sedatives used non-medically, Methaqualone/Sopor/Quaalude was used most commonly nonmedically (3%) whereas the least amount of non-medical use observed for Placidyl (0.3%).

Figure 1: Prevalence of NMUPD by different therapeutic classes
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Table 11: Top five prescription drugs ever used non-medically by the U.S. individuals
(Weighted %)
S.
No.

Pain relievers (%)

Tranquilizers (%)

Stimulants (%)

Sedatives (%)

1

Vicodin/Lortab/Lorcet
(9.26)
Darvocet/Darvon/Tylenol
with Codeine (8.67)

Valium /Diazepam
(6.04)
Xanax/Alprazolam,
Ativan/Lorazepam
(5.40)
Klonopin /Clonazepam
(1.77)
Soma (1.34)
Flexeril (1.21)

Methamphetamine,
Desoxyn/Methedrine (4.91)
Diet pills such as
amphetamines (3.45)

Methaqualone/Sopor/
Quaalude (2.67)
Barbiturates such as
Nembutal (1.08)

Ritalin/Methylphenidate
(2.14)
Dexedrine (1.05)
Dextroamphetamine (0.22)

Restoril/Temazepam
(0.41)
Phenobarbital (0.38)
Placidyl (0.25)

2

3
4
5

Percocet/Percodan/
Tylox (5.44)
Hydrocodone (3.96)
Codeine (3.48)

4.1.4 Descriptive statistics of NMUPD by therapeutic classes:
Table 12 presents descriptive statistics of non-medical users of prescription drugs by
different therapeutic classes. Uninsured individuals were more likely to use prescription
stimulants non-medically whereas individuals with private and public health coverage were more
likely to use sedatives non-medically. Tobacco use was highest among people using stimulants
non-medically (79%). Individuals using pain relievers non-medically were least likely to
abuse/depend on prescription drugs (15%) and were most likely to seek substance abuse
treatment (72%) than the other non-medical users.
Non-medical use of pain relievers was common among males (56%), those who had
either less than high school (29%) or high school education (29%). Individuals using
tranquilizers non-medically were more likely to be high school graduates (30%) and married
(31%). Individuals using stimulant non-medically were female (51%) and young adults of 18-25
years of age (39%). Most had some college education (31%), had never been married (66%), and
were also more likely to use tobacco (79%) and alcohol (91%). Fewer of the individuals used
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sedatives non-medically. Individuals engaging in non-medical use of sedatives were 35-49 years
old (28%), Whites (83%), employed (77%), and had either some college (28%) or more than
college education (29%).
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Table 12: Characteristics of non-medical users of prescription drugs by therapeutic classes (Weighted %)
Variable category
Health insurance
Private
Public
Uninsured
Gender
Male
Female
Age
12-17
18-25
26-34
35-49
50-64
Race/ethnicity
White, non-Hispanic
Black, non-Hispanic
Hispanics
Others
Education
Less than high school
High school graduate
Some college
College graduate
Marital status
Married
Widowed/divorced/separated
Never been married
Employer status
Employed

Pain relievers

Tranquilizers

Stimulants

Sedatives

P - value

58.27
14.21
27.52

61.55
11.64
26.81

55.98
12.01
32.01

62.09
14.76
23.16

0.0004

55.87
44.13

50.49
49.51

49.46
50.54

51.66
48.34

<0.0001

12.46
34.08
20.05
23.89
9.52

8.78
33.97
22.50
21.44
13.31

13.27
39.06
20.34
21.98
5.35

12.62
22.31
18.37
27.56
19.15

<0.0001

74.93
8.67
11.55
4.85

80.07
6.55
9.69
3.69

78.72
5.55
9.82
5.91

82.67
6.29
7.01
4.03

<0.0001

28.55
29.37
26.38
15.70

24.25
30.39
25.42
19.93

28.94
23.23
30.63
17.20

26.01
17.61
27.52
28.86

<0.0001

28.76
13.96
57.28

30.80
11.51
57.70

21.23
12.86
65.91

30.21
22.72
47.07

<0.0001

73.51

71.73

66.27

76.73

<0.0001
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Variable category
Unemployed
Other
Annual household Income
< $20, 000
$20, 000-$39,999
$40, 000-$74,999
≥$ 75,000
Reported general health
Excellent/very good/good
Fair/poor
Past year use of tobacco
Yes
No
Past year use of alcohol
Yes
No
Past year use of illicit drugs
Yes
No
Rx drug abuse/dependence
Yes
No
Treatment
Yes
No
Total Observation

Pain relievers

Tranquilizers

Stimulants

Sedatives

7.60
18.89

8.12
20.15

8.01
25.71

5.22
18.05

22.86
23.76
28.30
25.07

19.07
23.04
29.97
27.92

28.70
21.66
20.60
29.04

26.18
16.99
28.40
28.43

<0.0001

89.61
10.39

89.56
10.44

90.66
9.34

87.04
12.96

0.2185

70.72
29.28

73.44
26.56

78.76
21.24

63.93
36.07

<0.0001

88.61
11.39

91.75
8.25

90.73
9.27

87.09
12.91

<0.0001

100.00
00.00

100.00
00.00

100.00
00.00

100.00
00.00

-

15.39
84.61

19.12
80.88

23.67
76.33

26.72
73.28

<0.0001

72.08
27.92
3949 (5.52%)

70.01
29.99
1490 (2.33%)

67.91
32.09
1006 (1.27%)

68.33
31.67
238 (0.36%)

0.0257
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P - value

-

4.1.5 Logistic regression: association between health insurance and NMUPD
The joint test of significance was used to test if interaction terms contributed significantly
to the model. It is a likelihood ratio test where all the interaction terms to be tested are entered
into the model all at once. The unrestricted model contained the main effects and the interaction
terms. In the next step, restricted model was obtained by dropping the insignificant interaction
terms. The joint test of significance was then performed for the interaction terms that were
dropped from the model, and it was insignificant (p=0.2093). This suggested that these
interaction terms did not contribute significantly to the overall model, and for parsimonious
reasons these interaction terms were dropped from the unrestricted model. Table 13 shows the
final model used for the analysis.
Results of the logistic regression analysis showed that age, race, education, marital status,
type of health insurance, level of income, past-year use of tobacco and past-year use of alcohol
were significantly associated with NMUPD. Significant interaction effects were observed
between race and health insurance (p<0.001), education level and health insurance (p<0.05), and
income and health insurance (p<0.05).
Probability of NMUPD was found to decrease with increase in age. It was highest among
people aged 18-25 years (OR: 2.653, 95% CI: 1.967-3.578) and lowest among those aged 35-49
years (OR: 1.470, 95% CI: 1.102-1.961) when compared to 50-64 year old.
Controlling for all other variables in the model, individuals who were either widowed/
divorced/separated or had never been married were 36% (OR: 1.358, 95% CI: 1.071-1.720) and
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53% (OR: 1.534, 95% CI: 1.285-1.831) more likely to indulge in NMUPD when compared to
those who were married, respectively.
People engaging in risky health behaviors such as smoking and drinking were also at a
higher risk of NMUPD when compared to their counterparts. Persons who used tobacco in the
last year had 2.6 times greater odds (OR: 2.643, 95% CI: 2.305-3.032) of using prescription
drugs non-medically when compared to those who did not use tobacco in the last year. Similarly,
use of alcohol increased the probability of NMUPD by a factor of 2.4 (OR: 2.367, 95% CI:
1.913-2.928).
Results of the interaction effects showed that Hispanic people with private health
insurance had 24% (OR: 1.978, p<0.001) greater odds of engaging in NMUPD when compared
to uninsured Hispanic individuals. The interaction effect between education level and health
insurance was significant for high school graduates with public health insurance. These
individuals had a 14% (OR: 0.1773, p<0.05) lower likelihood of using prescription drugs nonmedically when compared to uninsured high school graduates (p<0.05). Likelihood of using
prescription drugs non-medically decreased with increasing income among individuals with
private health insurance. Privately insured individuals reporting family income less than $20,000
were 11% (OR: 1.1081, p<0.05) more likely to engage in NMUPD when compared to uninsured
individuals with family income less than $20,000. This likelihood decreased to 7% among the
privately insured individuals with family income of $40, 000 - $75,000 when compared to
uninsured individuals with family income of $40,000-$74,999 (OR: 1.1066, p<0.01).

67

Table 13: Logistic regression model: association between health insurance and NMUPD
Variable category

Odds ratio

95% confidence interval

P - value

Health insurance
Private
Public

0.625
0.309

0.357-1.097
0.116-0.821

0.1013
0.0185

Ref

-

-

0.941
Ref

0.839-1.056
-

0.3016
-

2.625
2.653
1.882
1.470
Ref

1.742-3.956
1.967-3.578
1.400-2.530
1.102-1.961
-

<0.0001
<0.0001
<0.0001
0.0087
-

0.641
0.427
0.586
Ref

0.405-1.017
0.323-0.565
0.337-1.018
-

0.0588
<0.0001
0.0581
-

1.657
1.156
1.512
Ref

1.056-2.602
0.747-1.789
0.961-2.377
-

0.0281
0.5162
0.0735
-

1.358
1.534
Ref

1.071-1.720
1.285-1.831
-

0.0114
<0.0001
-

1.196
1.026
Ref

0.998-1.434
0.869-1.212
-

0.0526
0.7621
-

0.798
0.866
0.702
Ref

0.557-1.142
0.612-1.228
0.494-0.997
-

0.2168
0.4202
0.0483
-

1.204
Ref

0.971-1.493
-

0.0906
-

2.643
Ref

2.305-3.032
-

<0.0001
-

Uninsured
Gender
Male
Female
Age
12-17
18-25
26-34
35-49
50-64
Race
Black, non-Hispanic
Hispanic
Others
White, non-Hispanic
Education
Less than high school
High school graduate
Some college
College graduate
Marital status
Widowed/ divorced/separated
Never been married
Married
Employment status
Unemployed
Other (including not in labor force)
Employed
Annual household income
< $20, 000
$20, 000-$39,999
$40, 000-$74,999
≥ $75,000
Reported general health
Fair/poor
Excellent/very good/good
Smoking
Yes
No
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Variable category
Use of alcohol
Yes
No

Odds ratio
2.367
Ref
Interaction effects

95% confidence interval

P - value

1.913-2.928
-

<0.0001
-

Race × Insurance
Black × private insurance
Black × public insurance
Black × uninsured

0.608
0.824
Ref

0.329-1.121
0.460-1.474
-

0.1107
0.5137
-

Hispanic × private insurance
Hispanic × public insurance
Hispanic × uninsured

1.237
1.179
Ref

0.6293-2.4320
0.736-1.891
-

0.5372
0.4932
-

Others × private insurance
Others × public insurance
Others × uninsured

0.967
2.168
Ref

0.497-1.883
0.682-6.890
-

0.9225
0.1898
-

Education × Insurance
Less than high school × private insurance
Less than high school × public insurance
Less than high school × uninsured

0.794
1.807
Ref

0.463-1.362
0.758-4.307
-

0.4025
0.1817
-

High school graduate × private insurance
High school graduate × public insurance
High school graduate × uninsured

0.872
0.8614
Ref

0.532-1.428
0.5006-1.4821
-

0.5850
0.5900
-

Some college × private insurance
Some college × public insurance
Some college × uninsured

0.717
1.770
Ref

0.434-1.185
0.728-4.303
-

0.1946
0.2081
-

Income × Insurance
Le20K × private insurance
Le20K × public insurance
Le20K × uninsured

1.108
1.388
Ref

0.6650-1.8464
0.786-2.453
-

0.6936
0.2589
-

Le40K × private insurance
Le40K × public insurance
Le40K × uninsured

1.207
1.178
Ref

0.800-1.821
0.660-2.101
-

0.3694
0.5802
-

Le75K × private insurance
Le75K × public insurance
Le75K × uninsured
Number of Observations
P-value for joint test of significance for the
interaction terms that were not significant

1.0666
1.485
Ref

0.6635-1.7148
0.768-2.874
42759
0.2093

0.7900
0.2398
-
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Model fitness:
The Hosmer and Lemeshow goodness-of-fit test was conducted for the final model (unweighted). The result was significant (p<.0001) suggesting that model does not adequately
describe the non-medical use of prescription drugs.
Although the Hosmer and Lemeshow test failed, percent concordant value and AUROC
value were relatively high i.e., around 76.2%, and this indicates model correctly distinguishes
between people who use prescription drugs non-medically vs. those who do not use prescription
drugs non-medically.
The r square value for the model was 0.0863. This suggested that nine percent of the
variability in the NMUPD is explained by independent variables used in the model.

4.2 Association between health insurance and prescription drug abuse/dependence
4.2.1 Characteristics of prescription drugs abusers/dependents:
Out of the 5,190 non-medical users of prescription drugs, 774 (13%) reported abuse or
dependence on prescription drugs. Characteristics of these individuals are presented in Table 14.
Sixty-six percent of the individuals who abused or were dependent on prescription drugs had
health insurance. These individuals were also more likely to use tobacco in the previous year
(76%). However, there was no significant difference in the use of alcohol and illicit drugs among
those who abused/were dependent on prescription drugs when compared to those who did not
abuse/were dependent on them. More of prescription drug abusers/dependents used treatment
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services for non-medical use, abuse/dependence on prescription/illicit drugs (76%) compared to
those who did not abuse/were dependent on them (71%).
Socio-demographic characteristics of the prescription drug abuser/dependents indicated
that more than half were males (51%). Prescription drug abuse/dependence increased with age
(p<0.05), and it was highest in the age group 26-64 years (49%). Whites had greater percentage
of abuse or dependence on prescription drugs (72%) when compared to other races (28%). There
was a significant relationship between prevalence of prescription drug abuse/dependence and
education. Individuals with less than a high school education were most likely to abuse/depend
on prescription drugs (37%). More than three-fourths of the individuals abusing/depending on
prescription drug were unmarried (79%), and employed (86%) at the time of survey. Prescription
drug abuse/dependence was lowest among individuals reporting family income $40,000-$74,999
(22%). This indicates that abuse/depend on prescription drugs was inversely related to the
income. Like NMUPD, prescription drug abuse/dependence was higher among people reporting
excellent/very good/good health (81%) when compared to those reporting fair/poor health (19%).
Table 14: Characteristics of prescription drug abusers/dependents (weighted %)
Variable category
Health insurance
Yes
No
Gender
Male
Female
Age
12-17
18-25
26-64
Race
White, non-Hispanic

Abuse or dependence on prescription drugs
Yes
No

P - value

65.71
34.29

75.71
24.29

0.0007

51.07
48.93

53.22
46.78

0.0623

16.54
34.20
49.26

12.48
31.62
55.90

0.0348

71.75

75.54

0.9301
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Variable category
Others
Education
Less than high school
High school graduate
College
Marital status
Married
Unmarried
Employment status
Employed
Unemployed
Annual household income
< $20, 000
$20, 000-$39,999
$40, 000-$74,999
≥ $75,000
Reported general health
Excellent/very good/good
Fair/poor
Past year use of tobacco
Yes
No
Past year use of alcohol
Yes
No
Past year use of illicit drugs
Yes
No
Treatment
Yes
No
Total Observation

Abuse or dependence on prescription drugs
Yes
No
28.25
24.46

P - value

37.42
26.71
35.87

27.40
27.46
45.14

<0.0001

21.22
78.78

32.33
67.67

0.0003

86.33
13.67

91.39
8.61

<0.0001

28.08
26.37
21.55
24.00

21.48
21.99
29.93
26.60

0.0109×

81.09
18.91

91.19
8.81

<0.0001

77.58
22.42

66.76
33.24

<0.0001

83.75
16.35

87.85
12.15

0.4057

99.99
0.01

99.73
0.27

0.5218

76.23
23.77
774 (14.91%)

70.92
29.08
4416 (85.09%)

<0.0001
-

4.2.2 Logistic regression: association between health insurance coverage and prescription
drug abuse/dependence:
Logistic regression analysis was performed to determine the relationship between sociodemographic factors and past-year abuse/dependence on prescription drugs among the U.S.
individuals younger than 65 years. As shown in Table 15, the likelihood ratio test was performed
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to see if interaction terms contributed significantly to the model. The chi square test value for the
fully interacted model was not significant (p=0.1342). This indicated that interaction terms did
not contribute significantly to the full model. Thus, all the interaction terms were dropped from
the full model.
Health insurance (p<0.05), age (p<0.01), marital status (p<0.05), reported general health
status (p<0.01) and tobacco use (p<0.01) were significant predictors of past-year
abuse/dependence on prescription drugs.
Persons with health insurance were found to have 39% lower probability (OR: 0.607,
95% CI: 0.403-0.915) of prescription drug abuse/dependence as compared to uninsured
individuals at α=0.05. Age was another important predictor of prescription drug
abuse/dependence. Individuals aged 12-17 years had 90% higher likelihood (OR: 1.904, 95% CI:
1.117-3.246) of prescription drug abuse/dependence than those aged 26-64 years. Similarly,
individuals aged 18-25 years had 80% greater chances (OR: 1.804, 95% CI: 1.308-2.487) of
prescription drug abuse/dependence than the reference group. Unmarried people had three times
greater chances (OR: 2.555, 95% CI: 1.455-4.484) of abusing/becoming dependent on
prescription drugs as compared to those who were married. Probability of abuse/dependence on
prescription drugs increased by a factor of 2.3 (OR: 2.326, 95% CI: 1.448-3.737) among
individuals who reported fair/ poor health status when compared to those who reported
excellent/very good/good health status. Use of tobacco was significantly associated with
prescription drug abuse/dependence. Individuals who used tobacco had three times greater risk
(OR: 3.267, 95% CI: 2.204-4.841) of prescription drug abuse/dependence than those who did not
use tobacco in the past year.
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Table 15: Logistic regression: association between health insurance and prescription drug
abuse/dependence
Variable category
Health insurance
Yes
No
Gender
Male
Female
Age
12-17
18-25
26-64
Race
Others
White, non-Hispanic
Education
Less than high school
High school graduate
College
Marital status
Unmarried
Married
Employment status
Unemployed
Employed
Annual household income
<$ 20, 000
$20, 000-$39,999
$40, 000-$74,999
≥ $75,000
Reported general health
Fair/poor
Excellent/very good/good
Use of tobacco
Yes
No
Use of alcohol
Yes
No

Odds ratio

95% confidence
interval

P – value

0.607
Ref

0.403-0.915
-

0.0170
-

1.021
Ref

0.747-1.394
-

0.8982
-

1.904
1.804
Ref

1.117-3.246
1.308-2.487
-

0.0179
0.0003
-

0.690
Ref

0.470-1.013
-

0.0581
-

1.224
0.930
Ref

0.770-1.946
0.643-1.345
-

0.3935
0.6999
-

2.555
Ref

1.455-4.484
-

0.0011
-

1.422
Ref

0.974-2.076
-

0.0682
-

1.151
1.000
0.921
Ref

0.654-2.025
0.606-1.650
0.578-1.467
-

0.6257
0.9993
0.7286
-

2.326
Ref

1.448-3.737
-

0.0005
-

3.267
Ref

2.204-4.841
-

<0.0001
-

1.671
Ref

0.931-2.999
-

0.0854
-

Number of observations

3,629
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P value for the joint test of significance
for interaction

0.1342

Model fitness:
The Hosmer and Lemeshow goodness-of-fit test was insignificant (p=0.49) suggesting
that model adequately describe abuse/dependence on prescription drugs.
The percent concordant value of the model was 76.0%.
The value of AUROC was 0.776 for the model, indicating the model correctly
distinguishes between people who abuse/depend on prescription drugs vs. those who do not
abuse/depend on prescription drugs.
The r square value for the model was fairly low, around 0.0154, suggesting that only two
percent of the variability in the prescription drug abuse/dependence is explained by independent
variables used in the model.

4.3

Association between health insurance and use of substance abuse treatment

4.3.1 Descriptive statistics of users of substance abuse treatment:
In the 2007 NSDUH, the question about use of substance abuse treatment was asked only to
those people who had ever used either prescription drugs or illicit drugs non-medically. Among these
individuals, only 689 respondents answered the question about use of treatment services either for
NMUPD only or for both NMUPD and illicit drug use. Of these 689 respondents, only 503 (69%)
individuals reported that they had used substance abuse treatment for these health issues.
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Characteristics of these individuals are presented in Table 16. There was no statistically significant
difference in the use of treatment services among insured and uninsured individuals. Among those
who used substance abuse services, most had used tobacco (89%), alcohol (80%) and other illicit
drugs (77%) but comparatively lesser numbers of individuals abused or were dependent on
prescription drugs (19%).
Socio-demographic characteristics of the people seeking treatment suggested that males (69%)
were significantly more likely to receive treatment than females (31%). Number of people using
treatment services for the prescription drugs increased with the increasing age, and the use of treatment
services was highest among the people aged 26-64 years (63%). Whites (78%) were more likely to
receive substance abuse treatment than other race (22%). Individuals using treatment services were
most likely to be high school graduates (36%), unmarried (83%), employed (86%), belonged to lower
income level (34%) and reported excellent/very good/good health (84%).
Table 16: Characteristics of individuals who used substance abuse treatment (Weighted %)
Variable category
Health insurance
Yes
No
Gender
Male
Female
Age
12-17
18-25
26-64
Race
White, non-Hispanic
Others
Education
Less than high school
High school graduate

Received treatment

P - value

Yes

No

62.44
37.56

61.72
38.28

0.9214

69.04
30.96

72.65
27.35

0.0410

11.93
25.81
62.27

3.44
23.81
72.75

<0.0001*

78.05
21.95

77.30
22.70

0.0340

33.37
36.15

21.23
34.91

<0.0001
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Variable category
College
Marital status
Married
Unmarried
Employment status
Employed
Unemployed
Annual household income
< $20, 000
$20, 000-$39,999
$40, 000-$74,999
≥ $75,000
Reported general health
Excellent/very good/good
Fair/poor
Past year use of tobacco
Yes
No
Past year use of alcohol
Yes
No
Past year use of illicit drugs
Yes
No
NMU
Yes
No
Prescription drug abuse/dependence
Yes
No
Total Observation

Received treatment
Yes
No
30.48
43.86

P - value

16.94
83.06

31.90
68.10

0.0323

86.21
13.79

92.54
7.46

<0.0001

34.10
26.86
21.72
17.31

21.50
38.37
19.61
20.52

0.7710

84.09
15.91

86.64
13.36

0.3025

87.88
12.12

80.33
19.67

0.2113

80.31
19.69

77.65
22.35

0.1756

76.77
23.33

63.01
36.99

<0.0001

55.13
44.87

46.78
53.22

<0.0001

12.96
87.04
186 (27.00%)

<0.0001

18.46
81.54
503 (73.00%)

-

4.3.2 Logistic regression: association between health insurance and use of substance
abuse treatment
Likelihood ratio test was performed to see if interaction terms contributed significantly to
the model. This test is shown in Table 17. The joint test of significance showed that full model
containing all the interaction terms was not significant (p=0.2403). Thus, all the interaction terms
were dropped from the full model. The final model is represented in Table 17.
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Logistic regression analysis was conducted to determine the relationship between
independent variables and the use of substance abuse treatment for misuse of prescription/drugs.
The results suggested that education level was the only significant predictor of the use of
substance abuse treatment (p=0.01). Controlling for all other variables in the model, individuals
with high school education had 2.6 times greater odds (OR: 2.575, 95% CI: 1.243-5.332) of
using substance abuse treatment for prescription drug problems when compared to college
graduates. Individual with less than a high school education had 56% greater likelihood of using
substance abuse treatment for misuse of prescription drugs as compared to college graduates.
However, this relationship was insignificant at α =0.05 (OR: 1. 557, 95% CI: 0.480-5.047).
People with health insurance were found to have 37% greater odds (OR: 1.371, 95% CI: 0.6572.861) of using substance abuse treatment for misuse of prescription drugs as compared to
uninsured individuals. However, this relationship was not significant at α=0.05.
Table 17: Logistic regression: association between health insurance coverage and use of
substance abuse treatment
Variable category
Health insurance
Yes
No
Gender
Male
Female
Age
18-25
26-64
12-17
Race
Others
White, non-Hispanic
Education
Less than high school

Odds ratio

95% confidence interval

P - value

1.371
Ref

0.657-2.861
-

0.4001
-

0.783
Ref

0.362-1.696
-

0.5351
-

0.304
0.363
Ref

0.075-1.225
0.073-1.816
-

0.0940
0.2172
-

1.907
Ref

0.614-5.915
-

0.2640
-

1.557

0.480-5.047

0.4604
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Variable category
High school graduate
College
Marital status
Unmarried
Married
Employment status
Unemployed
Employed
Annual household income
< $20, 000
$20, 000-$39,999
$40, 000-$74,999
≥ $75,000
Reported general health
Fair/poor
Excellent/very good/good
Use of tobacco
Yes
No
Use of alcohol
Yes
No
Number of observations
Joint test of significance
P value for the joint test of significance
for interaction terms

Odds ratio
2.575
Ref

95% confidence interval
1.243-5.332
-

P - value
0.0109
-

0.985
Ref

0.414-2.347
-

0.9733
-

1.887
Ref

0.551-6.467
-

0.3120
-

2.386
2.232
1.280
Ref

0.871-6.540
0.469-3.241
0.516-3.178
-

0.0909
0.6718
0.5941
-

1.312
Ref

0.401-4.297
-

0.6358
-

2.101
Ref

0.680-6.491
-

0.1972
-

0.393
Ref

0.141-1.101
484

0.0755
-

0.2403

Model fitness:
The Hosmer and Lemeshow goodness-of-fit test conducted for the final model
(unweighted) was insignificant (p<.5530). The percent concordant value of the model was
68.0%. The value of AUROC was 0.684 for the model. The r square value for the model was
0.0818. These results indicate that the model was able to predict the observed and expected
outcome.
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4.4

Summary of results of the study
The results from the logistic regression analyses show that uninsured individuals were at

higher risk of NMUPD, their abuse and dependence than insured individuals. Age was found to
be an important predictor of NMUPD only. Younger individuals aged 18-25 years were more
likely to use prescription drugs non-medically than the individuals aged 50-64 years. Hispanic
individuals were less likely to use prescription drugs non-medically. Additionally, there were
significant interaction terms between race and health insurance, and Hispanic individuals with
private health insurance were more likely to use prescription drugs non-medically than uninsured
Hispanic individuals. Individuals with a high school education were found to have a greater
probability of NMUPD and use of substance abuse treatment. In contrast, publicly insured
individuals with a high school education were found to have lower probability of NMUPD.
Individuals reporting $40, 000 - $74,999 incomes were less likely to engage in NMUPD than
those reporting ≥$75,000 family incomes. Moreover, significant interaction effects were
observed between income and health insurance, and privately insured individuals reporting less
than $20,000 and $40,000-$74,999 were more likely to engage in NMUPD than their
counterparts. Unmarried individuals were found to have a greater likelihood of NMUPD, their
abuse and dependence than married individuals. Similarly, individuals using tobacco were also
found to have greater likelihood of NMUPD, their abuse and dependence than those who did not
use tobacco. Alcohol use was associated with NMUPD only, and individuals using alcohol were
found to be more likely to use prescription drugs non-medically than those who did not use
alcohol. These results have been shown in the Table 18 below.
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Table 18: Summary of logistic regression analyses conducted in the study
Dependent variables
Independent variable

NMUPD

Prescription drug
abuse/dependence

Use of substance
abuse treatment

Health insurance

Uninsured individuals
more likely
Young individuals more
likely
No association
Hispanics less likely
Individuals with less than
high school more likely

Uninsured individuals
more likely
No association

No association

No association
No association
No association

Unmarried individuals
more likely
No association
No association

Health status

Unmarried individuals
more likely
No association
Individuals with $40,00074,999 income less likely
No association

No association
No association
Individuals with
high school more
likely
No association

Tobacco use
Alcohol use
Hispanic × private insurance

Age
Gender
Race and ethnicity
Level of education

Marital status
Employment status
Family income

No association

No association
No association
No association

More likely

More likely among
individuals with poor
health
More likely

More likely

No association

No association

Interaction effects
More likely
Not applicable

Not applicable

Less than $20K × private
insurance
$40K-$75K × private insurance

More likely

Not applicable

Not applicable

More likely

Not applicable

Not applicable

High school graduate × public
insurance

Less likely

Not applicable

Not applicable
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No association

CHAPTER 5 – DISCUSSION
This chapter presents a discussion of the results of this study. It starts with discussion of
the results and is followed by the limitations, strengths, recommendations for future research and
conclusions.
5.1

Effect of health insurance on NMUPD, their abuse/dependence
The first aim of this study was to examine the relationship between health insurance and

NMUPD, their abuse and dependence, and how this relationship is modified by different
covariates. This was achieved by performing multiple logistic regression analyses. The used
model predicted NMUPD, their abuse and dependence as a function of health insurance, sociodemographic, economic, health-behavioral characteristics, and first order interactions between
health insurance, socio-demographic, economic and health-behavioral characteristics.
Eighty-two percent of the respondents were insured, and the majority had private health
insurance (69%). Eight percent of the sample reported using prescription drugs non-medically.
One percent of the entire sample and 13% of NMUPD reported abuse dependence on
prescription drugs. Prevalence rate of prescription drug abuse/dependence in this study was
similar to those observed by other researchers [5, 7, 8, 25, 91]. Approximately, six percent of the
sample, 73% of non-medical users and 76% of the prescription drug abusers/dependents reported
some use of substance abuse programs. NMUPD, abuse and dependence was highest among
uninsured. This differential behavior between uninsured and insured individuals could be driven
by the fact that those with health insurance were in higher economic strata, more educated, in
better physical condition and perhaps wise enough to abstain from problem health behaviors.
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Consistent with prior research, this study found that males were more likely to be uninsured
(54%). Most of the adolescents aged 12-17 years had public health insurance (27%), whereas
individuals aged 35 years and older were more likely to have private health insurance (33%).
Whites represented a major proportion of the population (66%) and they commonly had private
health insurance (74%). Hispanics were more mostly uninsured (31%). Private health insurance
was also common among those who had a college education, were married, employed, reported
higher family income (>$75,000) and were in good health. These individuals were also less
likely to use tobacco and illicit drugs. These results are similar to a published report suggesting
that the sample is representative of the U.S. population [128].
In the overall sample, most of the individuals used pain relievers non-medically (6%) and
fewer of them used sedatives (0.4%). These numbers are similar to other studies except for
sedatives. Becker et al. (2007) reported higher prevalence of sedatives; this could be due to
differences in the samples. Becker et al. conducted their analysis among 18-80 year old
individuals whereas we conducted analysis among 12-64 year old individuals.
These results hold true in multivariate logistic regression analysis. Risk factors for
prescription drug abuse/dependence were mostly similar to the risk factors for NMUPD. Health
insurance was an important predictor of NMUPD, their abuse and dependence. Individuals with
public health insurance were found to be 69% less likely to use prescription drugs nonmedically. This finding was similar to the finding of the previous studies which found uninsured
individuals to be 1.2- 2.0 times more likely to use prescription drugs non-medically than the
insured individuals [5, 8, 71]. In contrast, Kroutil, et al. (2006) found individuals with ‗other‘
type of health insurance to be least likely to use of stimulants non-medically (O.R.-0.29, 95% CI:
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0.19-0.44) [71]. Interestingly, this study found insured individuals to be 39% less likely to
abuse/depend on prescription drugs than the uninsured individuals. Previous studies did not find
any significant association between health insurance and prescription drug abuse/dependence [5,
7].
An important contribution of this thesis is to identify specific subgroups of the population
where providing insurance will be most crucial. This study found significant interaction effect
between Hispanic race and private insurance; income category less than $20,000 and private
insurance; income category $40,000-$74,999 and private insurance; and high school education
and public health insurance. Hispanic people with private health insurance had 24% (O.R.-1.237,
p<0.001) greater risk of using prescription drugs non-medically when compared to the uninsured
Hispanic individuals. Privately insured individuals reporting less than $20,000 as family income
were found to have 11% (O.R.-1.1081, p<0.05) higher risk of using prescription drugs nonmedically whereas privately insured individual reporting family income $40,000-$74,999 had
seven percent (O.R.-1.0666, p<0.05) higher risk of using prescription drugs non-medically when
compared to the uninsured individuals having family income $40,000-$74,999. Publicly insured
individuals with high school education were found to be 14% (OR: 0.8614, p<0.05) less likely to
use prescription drugs non-medically when compared to the uninsured individuals with high
school education (p<0.05).
Hispanic people with private health insurance have been found to be at greater risk of
using prescription drugs non-medically when compared to the uninsured Hispanic individuals.
This indicates that even among those who have health insurance certain sub groups (like
Hispanics) are at increased risk of NMUPD. High prevalence of NMUPD among insured
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Hispanics can be due to acculturation to the US culture and lower education. Studies have found
acculturated Hispanics to be more likely to engage in NMUPD and illicit drug use than the nonacculturated Hispanics [129, 130]. Hispanic people have also been known to have lower
education level and high school dropout rate [131]. Therefore, they are more likely to be
uninformed about the harms of NMUPD. If this is case, then increasing awareness about the
harms of NMUPD might help in addressing the problem of NMUPD among Hispanic
individuals.
Increasing awareness about harms of NMUPD is also important among privately insured
individuals with lower family income (<$20,000) as they were found to have higher risk of using
prescription drugs non-medically than the privately insured individual with higher family income
($40,000-$75,000). Previous studies report mixed association between income and NMUPD.
Individuals with lower family incomes are less likely to be educated, and more likely to be
unaware of the harms of NMUPD [132]. This predisposes them to higher risk of NMUPD than
those with higher income.
In contrast to the above mentioned sub groups, publicly insured individuals with a lower
level of education were less likely to use prescription drugs non-medically than the uninsured
individuals with lower education. Prior literature indicates that individuals with lower education
level are at greater risk of NMUPD than individuals with higher level of education [6, 8, 25, 36].
This study adds knowledge to this area and we demonstrate that providing some form of health
coverage to those who have lower education might help in controlling NMUPD.
Overall, uninsured individuals are more likely to use prescription drugs non-medically,
abuse and depend on them. Possible reasons could be imprudent drug use, unawareness about
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prescription drug misuse, work environment. This could be due to lower education; infrequent
access to the health care provider which decreases their chances of getting knowledge about
judicious use of prescription drugs and harms of their non-medical use, abuse and dependence.
Uninsured individuals might be employed in work place that lack substance abuse policies and
this gives them the opportunity to misuse prescription drugs without fear of losing their
livelihood.
On the other hand, insured individuals have better access to health care provider and are
more likely to gain information about the proper use of prescription drugs, harms of prescription
drug misuse which might discourage them from these risky behaviors. Individuals with health
coverage are also more likely to be educated and as a result, more likely to perceive the risk, and
understand the sign and symptoms of these problem health behaviors. They might have health
coverage through the employer which makes them avoid NMUPD, their abuse and dependence
due to fear of losing job.

5.2.

Effect of other independent variables on NMUPD, their abuse/dependence:
Results from logistic regression analysis support our hypothesis that younger individuals

are at higher risk of NMUPD, their abuse and dependence than the older individuals. Probability
of NMUPD was found to be highest among 18-25 year old individuals and lowest among 35-49
year old individuals. Similarly, probability of abuse/depend on prescription drugs was highest
among 12-17 year old individuals. Prior literature suggests mixed relationship between age and
prescription drug abuse/dependence. Consistent with our findings, some authors have found
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younger individuals to be 3-37 times more likely to abuse/depend on prescription drugs [7, 12,
25, 36, 71, 133]. On the other hand, Simon-Wastila et al. (2004) and Becker et al. (2007) found
younger individuals to be 50%-80% less likely to abuse/depend on prescription drugs [5, 9]. The
higher risk of prescription drug abuse/dependence among younger individuals could be due to
either the age of onset of drug use or the age of onset of NMUPD. A previous study has found
initiation of drug use before the age of 15 as one of the predictors of prescription drug
abuse/dependence [134]. Another study found that individuals who start NMUPD at the age of
13 years or before have higher risk of developing prescription drug abuse/dependence than those
who start NMUPD after 21 years of age [7]. Similar to previous studies, individuals in this study
who used prescription drugs non-medically, abused/were dependent on them were also found to
have greater use of tobacco and alcohol [94, 95, 135, 136]. It is possible that they might be using
tobacco and alcohol along with prescription drugs. Concomitant use of prescription drugs and
other substances can lead to harmful drug-drug interactions and other life threatening
consequences.
Moreover, there was strong association between use of tobacco and NMUPD, their abuse
and dependence. However use of alcohol was only related to NMUPD. In this study, use of
tobacco, alcohol, and illicit drugs was found to be significantly higher among people indulging in
NMUPD, their abuse and dependence. These finding are similar to the findings of the previous
studies [5, 9, 36]. It is possible that most of the non-medical users/abusers/dependents of
prescription drugs are smokers, drinkers and illicit drug users and they misuse prescription drugs
either along with tobacco, alcohol, and illicit drugs or when they do not have access to tobacco,
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alcohol and illicit drugs. In these cases, these individuals are at higher risk of perceiving
NMUPD, their abuse and dependence as less harmful than the use of tobacco and alcohol.
Besides people indulging in risky behavior, people who were single like unmarried
people were found to have higher likelihood of NMUPD, and their abuse/dependence than the
married people. Other researchers have also reported similar finding in their studies where
individuals who had never been married had 10%-45% greater odds of using prescription drugs
non-medically and individuals who were widowed/ divorced/separated had 20%-45% greater
odds of using prescription drugs non-medically when compared to the married individuals [5, 9,
12, 36, 137]. Similarly, unmarried individuals were also found to have 1.2-2.7 times higher risk
of prescription drug abuse/dependence than the married individuals [5, 25, 36, 80]. It is very
likely that unmarried/widowed/ divorced/separated or those who had never been married might
have weak social bonds. Research has shown that individuals with weak bonds with the family,
friends, school, work, religion, and other aspect of traditional society are less likely to engage in
responsible behavior, refrain from drug abuse and other problem behaviors [89, 138]. Also,
married individuals are less likely to be alone and more likely to take decision together. Support
of the spouse and good decision making help married individuals to be more responsible toward
their behavior and thereby avoid problem health behaviors [139].
Controlling for all other variables in the model, health status was found to be associated
with prescription drug abuse/dependence but not with NMUPD. Individuals reporting fair/poor
healths in this study were 2.5 times more likely to use abuse/depend on prescription drugs when
compared to those who reported excellent/very good/good health. Some of the prior studies also
suggest that individuals reporting fair/poor are 2.04 to 2.4 more likely to abuse/dependence on
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prescription drugs than those reporting excellent/very good/good health [7, 9, 91]. In contrast to
our study, Simoni-Wastila et al. (2008) found 48%-51% lower risk of abuse/dependence on
prescription drugs among adolescents reporting fair/poor health when compared to those who
reported excellent health [47]. This could be either due to difference in the samples or due to
different definition of misuse of prescription drugs. Higher prescription drug abuse/dependence
among people reporting fair/poor health could be due the reason that these individuals as such
have been observed to more likely to use prescription drugs [140, 141] which predisposes them
to their abuse/dependence in the long run. It is possible that these individuals might be self
medicating for some unrecognized suffering like pain, anxiety, distress etc which increases their
risk of prescription drug abuse/dependence [142-145].

5.3

Effect of health insurance on the use of substance abuse treatment
The second aim of this study was to determine the relationship between health insurance

and probability of seeking treatment for nonmedical use/abuse/dependence on prescription drugs
and how different covariates modify the relationship between health insurance and probability of
seeking treatment for nonmedical use/abuse/dependence on prescription drugs.
The data revealed that a large number of non-medical users of prescription drugs (73%)
and prescription drug abusers/dependents (76%) used substance abuse treatment. These results
are dissimilar to the previous literature [80]. High use of treatment services among this sub group
of population could be because the study was not able to separate out the use of substance abuse
treatment for the misuse of prescription drugs from the use of substance abuse treatment for the
abuse/dependence on alcohol.
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Although NMUPD, their abuse and dependence was higher among uninsured individuals
but the use of substance abuse treatment did not vary by the health insurance status of an
individual. Results from the Logistic regression analysis support this observation and health
insurance was not an important predictor of use of substance abuse treatment for misuse of
prescription drugs. This could be because the purpose of health insurance is to subsidize the cost
of the treatment and most of these treatments institutions already provide subsidized services to
the patients 1) either for no charge and/or using sliding fee scale where payment for the
substance abuse treatment is based on an individuals‘ income and other factors besides health
insurance, 2) through other payment assistance. These payment assistances might be helpful to
the lower income and uninsured individuals who could not seek treatment due to cost as a
barrier.
Use of substance abuse treatment was significantly associated with education level and
individuals with high school education were 2.6 times more likely to use substance abuse
treatment when compared to the college graduates. Prior studies have found mixed relationship
between education and use of treatment services. Similar to our study, Wu et al., (2003) and
Waehrer et al. (2008) found that use of substance abuse services decreased significantly with an
increase in level of education [60, 62], whereas Weisner and colleagues (2002) found that
individuals with higher education were more likely to use treatment services than those having
lower education [104]. Strong association between use of substance abuse treatment and high
school education could be because of highest prevalence of NMUPD (29%), their abuse and
dependence (36%) among this group. On the other hand, NMUPD (18%), their abuse and
dependence (37%) was lowest among individuals having college education. So, it is possible that
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they will be less likely to seek treatment. Individuals with lower education are less likely to be
aware of the harms of misuse use of prescription drugs and are thus, less likely to perceive the
need for the treatment. Other reasons could be stigma [104, 146], lack of information and
confidence in the treatment [147-149]

5.4

Effect of health insurance on non-medical use of different therapeutic classes of

prescription drugs
The last aim of this study was to examine whether non-medical use of different
therapeutic classes of prescription drugs varies with health insurance. This was done by
performing chi square tests which estimated the bivariate associations between non-medical use
of different therapeutic classes of prescription drugs and health insurance.
The results from the chi square test show that individuals with private health insurance
were more likely to use tranquilizers (62%) and sedatives (62%). Previous studies have not
looked into the association between type of health insurance and non-medical use of tranquilizers
and sedatives. There is only one study that examined the association between health insurance
status and non-medical use of sedatives and tranquilizers and in this study individuals who were
either uninsured or had Medicaid coverage were more likely to use tranquilizers and sedatives
non-medically than their counterparts [5].
Uninsured individuals in this study were significantly more likely to use stimulants
(32%). Kroutil and colleagues (2006) found similar results in their study. In fact, their analysis
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indicates that individuals with any kind of health insurance are less likely to use stimulants nonmedically than the uninsured individuals [71].
Prevalence of NMUPD was lowest among individuals having public health insurance and
they were more likely to use pain relievers non-medically (14%). Becker and colleagues (2008)
found that uninsured individuals or those who had Medicaid coverage were at higher risk of nonmedical use of opioids than the others [7].
Non-medical use of different therapeutic classes of prescription drugs seems unrelated to
their cost. Desoxyn and Butisol are stimulant and sedative medication respectively that were
found to be used most frequently non-medically in this study. Analysis of the cost estimates of
these drugs suggests that Desoxyn is more expensive than Butisol [150, 151]. If cost would have
been a deciding factor for the non-medical use of these drugs, then non-medical use of Desoxyn
would have been higher among individuals having private health coverage and not among
uninsured individuals.
In summary, results from these bivariate analyses suggest that therapeutic classes of
prescription drug used non-medically vary with the type of health insurance.

5.5

Study implications
Results of this study have implication for treatment program developers, health care

providers and policy makers. The results of this study indicate that people with health insurance
are less likely to use prescription drugs non-medically and abuse/depend on them when
compared to the insured individuals. The risk for NMUPD and prescription drugs abuse and
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dependence was 69% and 39% lower for people with health coverage respectively. Health
insurance did not disproportionately impact people of different gender, age groups, marital
status, employment status, health status, alcohol use status and tobacco use status. However,
health insurance is likely to be important for at least one significant group e.g. high school
graduates. The study hypothesizes that for these individuals access to health care providers is
likely to reduce NMUPD among this group. Irrespective of health insurance, Hispanics and
individuals with less than $20,000 and $40,000-$74,999 incomes were more likely to use
prescription drugs non-medically. This could be due to poor knowledge about harmful effects of
the drugs in this group. This is an area of research that needs further investigation.
Besides being uninsured, individuals who were younger than 25 years of age were also
found to have higher risk of NMUPD, prescription drugs abuse/dependence. Previous literature
suggests that initiation of drug use at a younger age of 15 years or before and initiation of
NMUPD at the age of 13 years or before makes a person susceptible to these health problem
behaviors. Thus, it is important for the parents to be watchful for their kids about their drug use.
At this impressionable age, young minds are unaware of harms of NMUPD, prescription drugs
abuse/dependence. So, it might be helpful to provide counseling about the harms of these risky
health behaviors from early grade levels of the middle school years and this information can be
provided as part of the curriculum. These individuals were also found to have higher use of
tobacco and alcohol. Thus, the information about prescription drug misuse should be
supplemented with the information about other risky behaviors. Moreover, NMUPD was
strongly associated with alcohol and other substance use. Clearly, those who are more likely to
use tobacco and alcohol are also at higher risk of non-medical use and abuse of prescription
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drugs. Thus, physicians and treatment providers should screen individuals with NMUPD, their
abuse and dependence for substance abuse problems and vice versa. It is also important to make
these individuals understand that NMUPD, their abuse and dependence is as harmful as use of
tobacco, alcohol, and other substances.
There was strong association between marital status and NMUPD, their abuse and
dependence. Unmarried individuals were more likely to engage in these problem health
behaviors. As mentioned previously, these individuals are more likely to be alone, have weak
bonds with family, friends and are more likely to take bad decisions. So, it is important for them
to become socially active, get involved with their family and friends, and join some social groups
who can guide and help them with their choice of health behaviors. People reporting fair/poor
healths were more likely to abuse/depend on prescription drugs than those who reported
excellent/very good/good health. Thus, health care providers needs to be careful while
prescribing medicines with high abuse potential to these individuals and should regularly
monitor them for any sign and symptoms of NMUPD, their abuse and dependence.
Use of treatment services was not associated with health insurance. This indicates that
regardless of health insurance status those who want to get the treatment services can usually
obtain it. However, high school education had a significant impact of on the use of substance
abuse treatment. Educating individuals about the harms of prescription drug misuse, benefits and
effectiveness of treatment; and places where they are located might help in directing individuals
in need to these treatment facilities. Health professionals can help in addressing stigma by
providing treatment in an anonymous manner and by educating general public about NMUPD,
their abuse and dependence.

94

5.6

Limitations and Strengths

Limitations due to the design of the study:
The results of this study should be interpreted in the light of some limitations. This study
uses a cross-sectional data and therefore, cause and effect relationship between independent and
dependent variable cannot be established. A longitudinal study where individuals with and
without health insurance coverage are followed over time can provide more robust estimates.
Use of a continuous measure of NMUPD, abuse and dependence on prescription drugs
would have provided a clearer idea about the association between different covariates and nonmedical use/abuse/dependence on prescription drugs. However, this was not possible using the
2007 NSDUH dataset as around 90% of the respondents had reported no NMUPD in the past
year, 99% had reported no abuse/dependence on prescription drugs in the past year.
The impact of different types of health insurance on prescription drugs
abuse/dependence, and use of substance treatment services could not be examined due to
insufficient sample size across different health insurance categories.
Limitations due to the use of NSDUH dataset:
NSDUH excludes some important sub-populations like active military personnel, who
have been found to have significantly lower rates of illicit drug use. Also, individuals living in
institutional settings like prisons and residential drug use treatment centers, and those who are
homeless or living in a shelter are not included in NSDUH. These types of individuals have been
found to have higher rates of illicit drug use than the others [29]. Thus, the prevalence rates from
the NSDUH do not represent the entire population.
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Individuals living in institutional settings like prisons and residential drug use treatment
centers are more likely to get treatment from other public sources. It is likely that role of public
funding might be underestimated using the NSDUH. Thus, results obtained using NSDUH
dataset should be considered conservative. Information about these kinds of population can be
obtained from other sources like the Department of Defense (DoD) Survey of Health Related
Behaviors Among Active Duty Military Personnel and the Survey of Inmates in State and
Federal Correctional Facilities (SISCF) [152].
Respondents who reported that they use substance abuse treatment but were unsure
whether the treatment was for alcohol or for drug abuse and dependence were dropped from the
analysis. Thus, people who have used substance abuse treatment but failed to recall would be
missed and this might lead to underreporting of the use of substance abuse treatment services.
This study determines how socio-demographic factors will modify the effect of health
insurance on probability of seeking treatment for drug abuse and dependence among nonmedical users of prescription drugs. Besides socio-demographic factors, other behavioral factors
like personal motivation, perceived need and family and social pressure also play an important
role in coercing these individuals to seek treatment. However, this information is not collected in
the NSDUH and thus, we are not able to analyze these factors in our study.
NSDUH does not distinguish between individuals who use someone else‘s prescription
medication but use them properly for rightful medical conditions vs. those who use these
medications only for the feeling or the experience that these medications provide. If there is a
significant proportion of the population that uses somebody else‘s medication but in a rightful
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manner, then labeling them as non-medical users will lead to over estimation of non-medical
users which might bias the results of study.
Questions about prescription drug/s abuse and dependence were asked only to those
respondents who reported past year non-medical use of respective drug/s. It is possible that
individuals might engaged in NMUPD but have answered no to the above question due to social
desirability or due to stigma attached to NMUPD. These people might have also engaged in
prescription drug abuse and dependence but would be missed and this could lead to under
reporting of prescription drug abuse and dependence than the actual prevalence.
NSDUH relies on self report of the respondents which cannot be cross checked through
other sources like clinical and biological measures. Other biases like recall bias and social
desirability bias might also lead to under reporting of these problem health behaviors. However,
The NSDUH survey items have been evaluated for their accuracy and reproducibility of results
[26]. Moreover, technique like ACASI (Audio Computer Assisted Self Interview) is used for
questions that involve sharing of private, confidential and sensitive information. So, it is very
unlikely that self reporting bias will be large enough to affect the results of the study.
Strengths of the study:
1.

Generalizability of this study is high since this study uses data from NSDUH which

collects data from nationally representative sample of individuals living in households, persons
aged >12 years, and non-institutionalized civilian population.
2.

This is the first study to determine the differential impact of health coverage on

NMUPD/abuse/dependence on prescriptions drugs within subgroups of population. This was
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done by examining the interaction effect of health insurance and other socio-demographic
factors on NMUPD, their abuse and dependence.
3.

This study also shows that health insurance impacts therapeutic classes of prescription

drug used non-medically.
4.

Use of large sample size provided precise estimates of NMUPD, their abuse and

dependence and facilitated comparison with in subgroups of population.
5.

Use of ‗sampling weights‘ in this study helps to account for the complex sampling

methodology and for non-response in the NSDUH. This helps to obtain robust estimates of
NMUPD, their abuse and dependence.
6.

The method used for the analysis accounted for the complex survey design used in the

NSDUH to provide appropriate parameter estimates and standard errors thereby yielding
accurate estimates of NMUPD, their abuse and dependence.

5.7

Recommendations for future research
A more clear and concise definition of non-medical use of prescription drugs should be

employed in future studies so as to avoid any ambiguity regarding what constitutes non-medical
use of prescription drugs. This will help other researchers to replicate the results of previous
studies in broader and different populations. Use of Longitudinal studies can help in obtaining
unbiased estimates of the relationship between health insurance and non-medical
use/abuse/depend on prescription drugs; and use of substance abuse services for these health
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problems. It is also important to conduct studies using continuous measures of NMUPD,
abuse/dependence, and use of substance abuse services to get a clear understanding about how
change in health insurance and other covariates affects these dependent variables. Studies that
help in identifying various high risk groups for NMUPD, their abuse and dependence are
important as well. However, there is a need to conduct longitudinal studies that examine the
reason behind the greater risk of NMUPD among these individuals. Health insurance was an
important predictor of NMUPD, their abuse and dependence but we do not why someone with
health insurance is less likely to use prescription drugs non-medically, abuse and misuse them.
Health insurance was not related to the use of treatment services among people misusing
prescription drugs. However, we did not determine the source/s of payment (by type of health
insurance, out of pocket etc.) for the use of substance abuse services for misuse of prescription
drugs. It‘s important to find out the source/s of payment for use of treatment services for these
health problems as it is possible that health insurance might or might not cover the cost of
treatment.

5.8

Conclusions
This study contributes to the already existing literature on NMUPD, their abuse and

dependence and use of substance abuse treatment for these health problems. Around eight
percent of respondents in this study reported using prescription drugs non-medically and 13%
percent of the non-medical users also reported abuse/dependence on the prescription drugs. In
bivariate analyses, non-medical use of tranquilizers and sedatives was common among
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individuals with private health insurance. Uninsured individuals were more likely to use
stimulants. Individuals with public health insurance generally used sedatives non-medically.
In multivariate analyses, uninsured individuals were more likely to use prescription drugs
non-medically, abuse and depend on them when compared to the insured individuals. For the
first time, this study informs us about the differential impact of health coverage on
NMUPD/abuse/dependence on prescriptions drugs within subgroups of population. Results from
the study suggest that providing health coverage to the Hispanic people, those who had income
less than $20,000 and $40,000-$74,999 might not help in controlling the problem of NMUPD.
These sub groups are more likely to be unaware of the harms of NMUPD. Thus, increasing
awareness about the harms of NMUPD might be beneficial in managing the problem. However,
extending health coverage to the individuals with high school education seems beneficial in
addressing this problem. Besides the above motioned subgroups of population, individuals who
were young and engaged in risky behavior like tobacco use were also at higher risk of NMUPD
than the others. These individuals are less likely to perceive the harms of NMUPD so, it is
important that they should be made aware of the harms of NMUPD. Encouraging unmarried
people to become socially active might also help in controlling the problem of NMUPD, their
abuse and dependence among this group. Moreover, physicians need to be careful while
prescribing medication with huge abuse potential to people reporting poor/fair health
Extending health coverage to the uninsured individuals who misuse prescription
drugs/drugs might not help them in seeking substance abuse treatment. These individuals have
lesser education and seem to be unaware about the harms of misuse use of prescription drugs.
Therefore, do not perceive the need for the treatment. Also, they might lack knowledge about the
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benefits of the treatment; and might not use it due to stigma. Thus, there is a need to increase
awareness about the harms of prescription drug misuse, benefits of treatment, and address the
stigma associated with the use of substance abuse treatment.
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LIST OF ACRONYMS
ADHD - Attention Deficit Hyperactivity Disorder
AIDS - Acquired Immune Deficiency Syndrome
AOR – Adjusted Odds Ratio
AUDs - Alcohol Use Disorders
ADHD - Attention Deficit Hyperactivity Disorder
CI - Confidence Interval
CSA - The Controlled Substances Act
DAWN - Drug Abuse Warning Network
DSM-IV Diagnostic and Statistical Manual of Mental Disorders
ED - Emergency Department
HCV - Hepatitis C Virus
HIV - Human Immunodeficiency Virus
NESARC - National Epidemiologic Survey on Alcohol and Related Conditions
NIDA - National Institute on Drug Abuse
NLAES - National Longitudinal Alcohol Epidemiologic Survey
NMUPD - Non-Medical Use of Prescription Drugs
NSDUH - National Survey on Drug Use and Health
OTC - Over The Counter
SAMHSA - Substance Abuse and Mental Health Services Administration
USFDA - US Food and Drug Administration
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